



(Audio archived recordings of the committee meetings, corresponding to the date of the committee statement, *may possibly* be found at [www.njleg.state.nj.us](http://www.njleg.state.nj.us))

**FLOOR AMENDMENT STATEMENT:** No

**LEGISLATIVE FISCAL ESTIMATE:** No

**VETO MESSAGE:** Yes

**GOVERNOR'S PRESS RELEASE ON SIGNING:** Yes

**FOLLOWING WERE PRINTED:**

To check for circulating copies, contact New Jersey State Government Publications at the State Library ([609\) 278-2640 ext.103](tel:6092782640) or <mailto:refdesk@njstatelib.org>)

**REPORTS:** No

**HEARINGS:** No

**NEWSPAPER ARTICLES:** No

§1 - C.45:14-82.1  
Title 24.  
Subtitle 1.  
Chapter 6N.  
Drug Pricing  
§2 - C.24:6N-1

P.L. 2019, CHAPTER 404, *approved January 21, 2020*  
Senate, No. 2389 (*Second Reprint*)

1 AN ACT concerning the disclosure of prescription drug price  
2 information and supplementing <sup>2</sup>[P.L.2003, c.280 (C.45:14-  
3 40 et seq.)] P.L.2006, c.84 (C.45:14-81 et seq.)<sup>2</sup> and Title 24 of  
4 the Revised Statutes.

5  
6 **BE IT ENACTED** by the Senate and General Assembly of the State  
7 of New Jersey:

8  
9 1. a. <sup>2</sup>[The New Jersey State Board of Pharmacy] As provided  
10 in subsection c. of this section, the Division of Consumer Affairs in  
11 the Department of Law and Public Safety<sup>2</sup> shall develop a  
12 prescription drug pricing disclosure website in order to make  
13 prescription drug price information available to New Jersey  
14 practitioners. The website shall have a dedicated link that is  
15 prominently displayed on the <sup>2</sup>[board's] division's<sup>2</sup> home page.

16 b. The website shall include, at a minimum, the following data  
17 elements, separated by therapeutic category:

18 (1) name of the product;

19 (2) whether the drug is brand name or generic;

20 (3) drug strength;

21 (4) per-unit wholesale acquisition cost of the drug, provided to  
22 the <sup>2</sup>[board] division<sup>2</sup> by pharmaceutical manufacturing companies  
23 pursuant to section 2 of P.L. , c. (C. ) (pending before the  
24 Legislature as this bill); and

25 (5) any disclaimers deemed appropriate by the <sup>2</sup>[board]  
26 division<sup>2</sup> <sup>1</sup>that are not inconsistent with State or federal law or  
27 regulations<sup>1</sup> .

28 c. The <sup>2</sup>[board] division<sup>2</sup> shall actively seek grant funds to  
29 implement the provisions of this section, and implementation shall  
30 be contingent upon the <sup>2</sup>[board] division<sup>2</sup> obtaining sufficient grant  
31 funds for the development, operation, and continued maintenance of  
32 the prescription drug pricing disclosure website. The <sup>2</sup>[board]

**EXPLANATION** – Matter enclosed in bold-faced brackets **[thus]** in the above bill is not enacted and is intended to be omitted in the law.

Matter underlined thus is new matter.

Matter enclosed in superscript numerals has been adopted as follows:

<sup>1</sup>Senate SHH committee amendments adopted June 3, 2019.

<sup>2</sup>Senate amendments adopted in accordance with Governor's recommendations January 13, 2020.

1 division<sup>2</sup> shall have the authority to enter into a contract for the  
2 administration of the <sup>2</sup>**board's** division's<sup>2</sup> responsibilities  
3 pursuant to this section. <sup>2</sup>The division shall establish the disclosure  
4 website no later than six months after it receives grant funds in an  
5 amount sufficient to develop and operate the website as provided in  
6 this subsection.<sup>2</sup>

7 d. Each State board and other entity that, under Title 45 of the  
8 Revised Statutes, regulates individuals with prescriptive authority in  
9 New Jersey shall advise the licensees of the board or entity at least  
10 once annually of the opportunity to access the prescription drug  
11 pricing disclosure website.

12  
13 2. a. For the purposes of the prescription drug pricing  
14 disclosure website required <sup>2</sup>**by the New Jersey State Board of**  
15 **Pharmacy**<sup>2</sup> pursuant to section 1 of P.L. , c. (C. ) (pending  
16 before the Legislature as this bill), each pharmaceutical  
17 manufacturing company that engages in prescription drug  
18 marketing, either directly or through the use of a pharmaceutical  
19 marketer, with a New Jersey practitioner as defined in section 2 of  
20 P.L.2003, c.280 (C.45:14-41), a practitioner's designee, or any  
21 member of a practitioner's staff, shall provide to the <sup>2</sup>**New Jersey**  
22 **State Board of Pharmacy** Division of Consumer Affairs in the  
23 Department of Law and Public Safety<sup>2</sup>, no later than <sup>1</sup>**January**  
24 **first, April first, July first, and October first** 30 days after the end<sup>1</sup>  
25 of each <sup>1</sup>quarter of the<sup>1</sup> calendar year, the current wholesale  
26 acquisition cost information for the pharmaceutical drugs or  
27 biological products marketed in the State by that company.

28 b. The provisions of this section shall only apply to  
29 prescription drug marketing engaged in by a pharmaceutical  
30 manufacturing company and a practitioner, a practitioner's  
31 designee, or any member of a practitioner's staff, while physically  
32 present in the state of New Jersey.

33 c. Any pharmaceutical manufacturing company that fails to  
34 comply with the requirements of this section shall be liable to a  
35 penalty as follows: for the first offense, not less than \$200 nor  
36 more than \$5,000; and, for the second and each succeeding offense,  
37 not less than \$1,000 nor more than \$20,000. The penalties shall be  
38 enforced by the Director of Consumer Affairs in the Department of  
39 Law and Public Safety in a summary proceeding in accordance with  
40 the "Penalty Enforcement Law of 1999," P.L.1999, c.274 (C.2A:58-  
41 10 et seq.).

42 d. For purposes of this section:

43 "Pharmaceutical marketer" means a person who, while employed  
44 by or under contract to represent a pharmaceutical manufacturing  
45 company, engages in prescription drug marketing activities.

1 "Prescription drug marketing" means any activity, including, but  
2 not limited to, in-person meetings, physical mailings, telephonic  
3 conversations, video conferencing, electronic mail, or facsimile,  
4 that provides educational or marketing information or materials  
5 regarding a prescription drug.

6 "Wholesale acquisition cost" means the pharmaceutical  
7 manufacturing company's list price for the pharmaceutical drug or  
8 biological product to wholesalers or direct purchasers in the United  
9 States for the most recent month for which the information is  
10 available, as reported in wholesale price guides or other  
11 publications of pharmaceutical drug or biological product pricing  
12 data, not including prompt pay or other discounts, rebates, or  
13 reductions in price.

14

15 3. This act shall take effect immediately.

16

17

18

19

20 \_\_\_\_\_  
21 Requires New Jersey State Board of Pharmacy to establish  
22 prescription drug pricing disclosure website and certain  
23 pharmaceutical manufacturing companies to provide prescription  
drug price information.

**SENATE, No. 2389**

---

**STATE OF NEW JERSEY**  
**218th LEGISLATURE**

---

INTRODUCED APRIL 5, 2018

**Sponsored by:**  
**Senator TROY SINGLETON**  
**District 7 (Burlington)**

**SYNOPSIS**

Requires New Jersey State Board of Pharmacy to establish prescription drug pricing disclosure website and certain pharmaceutical manufacturing companies to provide prescription drug price information.

**CURRENT VERSION OF TEXT**

As introduced.



1 AN ACT concerning the disclosure of prescription drug price  
2 information and supplementing P.L.2003, c.280 (C.45:14-40 et  
3 seq.) and Title 24 of the Revised Statutes.

4  
5 **BE IT ENACTED** by the Senate and General Assembly of the State  
6 of New Jersey:

7  
8 1. a. The New Jersey State Board of Pharmacy shall develop a  
9 prescription drug pricing disclosure website in order to make  
10 prescription drug price information available to New Jersey  
11 practitioners. The website shall have a dedicated link that is  
12 prominently displayed on the board's home page.

13 b. The website shall include, at a minimum, the following data  
14 elements, separated by therapeutic category:

15 (1) name of the product;

16 (2) whether the drug is brand name or generic;

17 (3) drug strength;

18 (4) per-unit wholesale acquisition cost of the drug, provided to  
19 the board by pharmaceutical manufacturing companies pursuant to  
20 section 2 of P.L. , c. (C. ) (pending before the Legislature as  
21 this bill); and

22 (5) any disclaimers deemed appropriate by the board.

23 c. The board shall actively seek grant funds to implement the  
24 provisions of this section, and implementation shall be contingent  
25 upon the board obtaining sufficient grant funds for the development,  
26 operation, and continued maintenance of the prescription drug pricing  
27 disclosure website. The board shall have the authority to enter into a  
28 contract for the administration of the board's responsibilities pursuant  
29 to this section.

30 d. Each State board and other entity that, under Title 45 of the  
31 Revised Statutes, regulates individuals with prescriptive authority in  
32 New Jersey shall advise the licensees of the board or entity at least  
33 once annually of the opportunity to access the prescription drug  
34 pricing disclosure website.

35  
36 2. a. For the purposes of the prescription drug pricing disclosure  
37 website required by the New Jersey State Board of Pharmacy  
38 pursuant to section 1 of P.L. , c. (C. ) (pending before the  
39 Legislature as this bill), each pharmaceutical manufacturing company  
40 that engages in prescription drug marketing, either directly or through  
41 the use of a pharmaceutical marketer, with a New Jersey practitioner  
42 as defined in section 2 of P.L.2003, c.280 (C.45:14-41), a  
43 practitioner's designee, or any member of a practitioner's staff, shall  
44 provide to the New Jersey State Board of Pharmacy, no later than  
45 January first, April first, July first, and October first of each calendar  
46 year, the current wholesale acquisition cost information for the  
47 pharmaceutical drugs or biological products marketed in the State by  
48 that company.

1       b. The provisions of this section shall only apply to prescription  
2 drug marketing engaged in by a pharmaceutical manufacturing  
3 company and a practitioner, a practitioner's designee, or any member  
4 of a practitioner's staff, while physically present in the state of New  
5 Jersey.

6       c. Any pharmaceutical manufacturing company that fails to  
7 comply with the requirements of this section shall be liable to a  
8 penalty as follows: for the first offense, not less than \$200 nor  
9 more than \$5,000; and, for the second and each succeeding offense,  
10 not less than \$1,000 nor more than \$20,000. The penalties shall be  
11 enforced by the Director of Consumer Affairs in the Department of  
12 Law and Public Safety in a summary proceeding in accordance with  
13 the "Penalty Enforcement Law of 1999," P.L.1999, c.274 (C.2A:58-  
14 10 et seq.).

15       d. For purposes of this section:

16       "Pharmaceutical marketer" means a person who, while employed  
17 by or under contract to represent a pharmaceutical manufacturing  
18 company, engages in prescription drug marketing activities.

19       "Prescription drug marketing" means any activity, including, but  
20 not limited to, in-person meetings, physical mailings, telephonic  
21 conversations, video conferencing, electronic mail, or facsimile, that  
22 provides educational or marketing information or materials regarding a  
23 prescription drug.

24       "Wholesale acquisition cost" means the pharmaceutical  
25 manufacturing company's list price for the pharmaceutical drug or  
26 biological product to wholesalers or direct purchasers in the United  
27 States for the most recent month for which the information is  
28 available, as reported in wholesale price guides or other publications  
29 of pharmaceutical drug or biological product pricing data, not  
30 including prompt pay or other discounts, rebates, or reductions in  
31 price.

32

33       3. This act shall take effect immediately.

34

35

36

#### STATEMENT

37

38       This bill requires the New Jersey State Board of Pharmacy to  
39 establish a prescription drug pricing disclosure website. In order to  
40 make this information available for the website, the bill further  
41 requires certain pharmaceutical manufacturing companies to provide  
42 prescription drug price information to the board.

43       Under the bill, the board is required to develop a prescription  
44 drug pricing disclosure website in order to make prescription drug  
45 price information available to New Jersey practitioners, who are  
46 individuals currently licensed, registered, or otherwise authorized in  
47 the State to administer or prescribe drugs in the course of  
48 professional practice. The website must have a dedicated link that



**S2389 SINGLETON**

1 is prominently displayed on the board's home page and include, at a  
2 minimum, the following data elements, separated by therapeutic  
3 category: (1) name of the product; (2) whether the drug is brand  
4 name or generic; (3) drug strength; (4) per-unit wholesale  
5 acquisition cost of the drug, provided to the board by pharmaceutical  
6 manufacturing companies as required by the bill; and (5) any  
7 disclaimers deemed appropriate by the board. Each State board and  
8 other entity that, under Title 45 of the Revised Statutes, regulates  
9 individuals with prescriptive authority in New Jersey is required to  
10 advise the licensees of the board or entity at least once annually of the  
11 opportunity to access the prescription drug pricing disclosure website.

12 The bill also requires that each pharmaceutical manufacturing  
13 company that engages in any form of prescription drug marketing,  
14 either directly or through the use of a pharmaceutical marketer, with a  
15 New Jersey practitioner, a practitioner's designee, or any member of a  
16 practitioner's staff, to provide to the board, no later than January first,  
17 April first, July first, and October first of each calendar year, the  
18 current wholesale acquisition cost information for the pharmaceutical  
19 drugs or biological products marketed in the State by that company.  
20 Any pharmaceutical manufacturing company that fails to comply  
21 with these requirements will be liable to a penalty as follows: for  
22 the first offense, not less than \$200 nor more than \$5,000; and, for  
23 the second and each succeeding offense, not less than \$1,000 nor  
24 more than \$20,000.

25 Under the bill, "wholesale acquisition cost" means the  
26 pharmaceutical manufacturing company's list price for the  
27 pharmaceutical drug or biological product to wholesalers or direct  
28 purchasers in the United States for the most recent month for which  
29 the information is available, as reported in wholesale price guides or  
30 other publications of pharmaceutical drug or biological product pricing  
31 data, not including prompt pay or other discounts, rebates, or  
32 reductions in price.

SENATE HEALTH, HUMAN SERVICES AND SENIOR  
CITIZENS COMMITTEE

STATEMENT TO  
**SENATE, No. 2389**

with committee amendments

**STATE OF NEW JERSEY**

DATED: JUNE 3, 2019

The Senate Health, Human Services and Senior Citizens Committee reports favorably and with committee amendments Senate Bill No. 2389.

As amended by the committee, this bill requires the New Jersey State Board of Pharmacy to establish a prescription drug pricing disclosure website. In order to make this information available for the website, the amended bill further requires certain pharmaceutical manufacturing companies to provide prescription drug price information to the board.

Under the bill as amended, the board is required to develop a prescription drug pricing disclosure website in order to make prescription drug price information available to New Jersey practitioners, who are individuals currently licensed, registered, or otherwise authorized in the State to administer or prescribe drugs in the course of professional practice. The website must have a dedicated link that is prominently displayed on the board's home page and include, at a minimum, the following data elements, separated by therapeutic category: (1) name of the product; (2) whether the drug is brand name or generic; (3) drug strength; (4) per-unit wholesale acquisition cost of the drug, provided to the board by pharmaceutical manufacturing companies as required by the bill; and (5) any disclaimers deemed appropriate by the board that are not inconsistent with State and federal law or regulations. Each State board and other entity that, under Title 45 of the Revised Statutes, regulates individuals with prescriptive authority in New Jersey is required to advise the licensees of the board or entity at least once annually of the opportunity to access the prescription drug pricing disclosure website.

The amended bill also requires that each pharmaceutical manufacturing company that engages in any form of prescription drug marketing, either directly or through the use of a pharmaceutical marketer, with a New Jersey practitioner, a practitioner's designee, or any member of a practitioner's staff, to provide to the board, no later than 30 days after the end of each quarter of the calendar year, the current wholesale acquisition cost information for the pharmaceutical

drugs or biological products marketed in the State by that company. Any pharmaceutical manufacturing company that fails to comply with these requirements will be liable to a penalty as follows: for the first offense, not less than \$200 nor more than \$5,000; and, for the second and each succeeding offense, not less than \$1,000 nor more than \$20,000.

Under the bill, "wholesale acquisition cost" means the pharmaceutical manufacturing company's list price for the pharmaceutical drug or biological product to wholesalers or direct purchasers in the United States for the most recent month for which the information is available, as reported in wholesale price guides or other publications of pharmaceutical drug or biological product pricing data, not including prompt pay or other discounts, rebates, or reductions in price.

COMMITTEE AMENDMENTS:

The committee amendments clarify that any additional disclaimers included by the State Board of Pharmacy on the prescription drug pricing website established under the bill are not to be inconsistent with State or federal law or regulations.

The committee amendments revise the reporting requirement for pharmaceutical manufacturers to provide that the required information is to be provided to the State Board of Pharmacy no later than 30 days after the end of each quarter of the calendar year, rather than by January 1, April 1, July 1, and October 1 of each calendar year.

# ASSEMBLY HEALTH AND SENIOR SERVICES COMMITTEE

## STATEMENT TO

[First Reprint]

**SENATE, No. 2389**

# **STATE OF NEW JERSEY**

DATED: DECEMBER 5, 2019

The Assembly Health and Senior Services Committee reports favorably Senate Bill No. 2389 (1R).

This bill requires the New Jersey State Board of Pharmacy to establish a prescription drug pricing disclosure website. In order to make this information available for the website, the bill further requires certain pharmaceutical manufacturing companies to provide prescription drug price information to the board.

Under the bill, the board is required to develop a prescription drug pricing disclosure website in order to make prescription drug price information available to New Jersey practitioners, who are individuals currently licensed, registered, or otherwise authorized in the State to administer or prescribe drugs in the course of professional practice. The website must have a dedicated link that is prominently displayed on the board's home page and include, at a minimum, the following data elements, separated by therapeutic category: (1) name of the product; (2) whether the drug is brand name or generic; (3) drug strength; (4) per-unit wholesale acquisition cost of the drug, provided to the board by pharmaceutical manufacturing companies as required by the bill; and (5) any disclaimers deemed appropriate by the board that are not inconsistent with State and federal law or regulations. Each State board and other entity that, under Title 45 of the Revised Statutes, regulates individuals with prescriptive authority in New Jersey is required to advise the licensees of the board or entity at least once annually of the opportunity to access the prescription drug pricing disclosure website.

The bill also requires that each pharmaceutical manufacturing company that engages in any form of prescription drug marketing, either directly or through the use of a pharmaceutical marketer, with a New Jersey practitioner, a practitioner's designee, or any member of a practitioner's staff, to provide to the board, no later than 30 days after the end of each quarter of the calendar year, the current wholesale acquisition cost information for the pharmaceutical drugs or biological products marketed in the State by that company. Any pharmaceutical manufacturing company that fails to comply with these requirements will be liable to a penalty as follows: for the first offense, not less than

\$200 nor more than \$5,000; and, for the second and each succeeding offense, not less than \$1,000 nor more than \$20,000.

Under the bill, "wholesale acquisition cost" means the pharmaceutical manufacturing company's list price for the pharmaceutical drug or biological product to wholesalers or direct purchasers in the United States for the most recent month for which the information is available, as reported in wholesale price guides or other publications of pharmaceutical drug or biological product pricing data, not including prompt pay or other discounts, rebates, or reductions in price.

As reported by the committee, this bill is identical to Assembly Bill No. 5449 (1R), which was amended, and also reported, by the committee on this date.

# ASSEMBLY, No. 5449

## STATE OF NEW JERSEY 218th LEGISLATURE

INTRODUCED MAY 23, 2019

**Sponsored by:**

**Assemblywoman ANNETTE QUIJANO**

**District 20 (Union)**

**SYNOPSIS**

Requires New Jersey State Board of Pharmacy to establish prescription drug pricing disclosure website and certain pharmaceutical manufacturing companies to provide prescription drug price information.

**CURRENT VERSION OF TEXT**

As introduced.



1 AN ACT concerning the disclosure of prescription drug price  
2 information and supplementing P.L.2003, c.280 (C.45:14-  
3 40 et seq.) and Title 24 of the Revised Statutes.

4  
5 **BE IT ENACTED** by the Senate and General Assembly of the State  
6 of New Jersey:

7  
8 1. a. The New Jersey State Board of Pharmacy shall develop a  
9 prescription drug pricing disclosure website in order to make  
10 prescription drug price information available to New Jersey  
11 practitioners. The website shall have a dedicated link that is  
12 prominently displayed on the board's home page.

13 b. The website shall include, at a minimum, the following data  
14 elements, separated by therapeutic category:

15 (1) name of the product;

16 (2) whether the drug is brand name or generic;

17 (3) drug strength;

18 (4) per-unit wholesale acquisition cost of the drug, provided to  
19 the board by pharmaceutical manufacturing companies pursuant to  
20 section 2 of P.L. , c. (C. ) (pending before the Legislature as  
21 this bill); and

22 (5) any disclaimers deemed appropriate by the board.

23 c. The board shall actively seek grant funds to implement the  
24 provisions of this section, and implementation shall be contingent  
25 upon the board obtaining sufficient grant funds for the development,  
26 operation, and continued maintenance of the prescription drug pricing  
27 disclosure website. The board shall have the authority to enter into a  
28 contract for the administration of the board's responsibilities pursuant  
29 to this section.

30 d. Each State board and other entity that, under Title 45 of the  
31 Revised Statutes, regulates individuals with prescriptive authority in  
32 New Jersey shall advise the licensees of the board or entity at least  
33 once annually of the opportunity to access the prescription drug  
34 pricing disclosure website.

35  
36 2. a. For the purposes of the prescription drug pricing disclosure  
37 website required by the New Jersey State Board of Pharmacy  
38 pursuant to section 1 of P.L. , c. (C. ) (pending before the  
39 Legislature as this bill), each pharmaceutical manufacturing company  
40 that engages in prescription drug marketing, either directly or through  
41 the use of a pharmaceutical marketer, with a New Jersey practitioner  
42 as defined in section 2 of P.L.2003, c.280 (C.45:14-41), a  
43 practitioner's designee, or any member of a practitioner's staff, shall  
44 provide to the New Jersey State Board of Pharmacy, no later than  
45 January first, April first, July first, and October first of each calendar  
46 year, the current wholesale acquisition cost information for the  
47 pharmaceutical drugs or biological products marketed in the State by  
48 that company.

1       b. The provisions of this section shall only apply to prescription  
2 drug marketing engaged in by a pharmaceutical manufacturing  
3 company and a practitioner, a practitioner's designee, or any member  
4 of a practitioner's staff, while physically present in the state of New  
5 Jersey.

6       c. Any pharmaceutical manufacturing company that fails to  
7 comply with the requirements of this section shall be liable to a  
8 penalty as follows: for the first offense, not less than \$200 nor  
9 more than \$5,000; and, for the second and each succeeding offense,  
10 not less than \$1,000 nor more than \$20,000. The penalties shall be  
11 enforced by the Director of Consumer Affairs in the Department of  
12 Law and Public Safety in a summary proceeding in accordance with  
13 the "Penalty Enforcement Law of 1999," P.L.1999, c.274 (C.2A:58-  
14 10 et seq.).

15       d. For purposes of this section:

16       "Pharmaceutical marketer" means a person who, while employed  
17 by or under contract to represent a pharmaceutical manufacturing  
18 company, engages in prescription drug marketing activities.

19       "Prescription drug marketing" means any activity, including, but  
20 not limited to, in-person meetings, physical mailings, telephonic  
21 conversations, video conferencing, electronic mail, or facsimile, that  
22 provides educational or marketing information or materials regarding a  
23 prescription drug.

24       "Wholesale acquisition cost" means the pharmaceutical  
25 manufacturing company's list price for the pharmaceutical drug or  
26 biological product to wholesalers or direct purchasers in the United  
27 States for the most recent month for which the information is  
28 available, as reported in wholesale price guides or other publications  
29 of pharmaceutical drug or biological product pricing data, not  
30 including prompt pay or other discounts, rebates, or reductions in  
31 price.

32

33       3. This act shall take effect immediately.

34

35

36

#### STATEMENT

37

38       This bill requires the New Jersey State Board of Pharmacy to  
39 establish a prescription drug pricing disclosure website. In order to  
40 make this information available for the website, the bill further  
41 requires certain pharmaceutical manufacturing companies to provide  
42 prescription drug price information to the board.

43       Under the bill, the board is required to develop a prescription  
44 drug pricing disclosure website in order to make prescription drug  
45 price information available to New Jersey practitioners, who are  
46 individuals currently licensed, registered, or otherwise authorized in  
47 the State to administer or prescribe drugs in the course of  
48 professional practice. The website must have a dedicated link that



1 is prominently displayed on the board's home page and include, at a  
2 minimum, the following data elements, separated by therapeutic  
3 category: (1) name of the product; (2) whether the drug is brand  
4 name or generic; (3) drug strength; (4) per-unit wholesale  
5 acquisition cost of the drug, provided to the board by pharmaceutical  
6 manufacturing companies as required by the bill; and (5) any  
7 disclaimers deemed appropriate by the board. Each State board and  
8 other entity that, under Title 45 of the Revised Statutes, regulates  
9 individuals with prescriptive authority in New Jersey is required to  
10 advise the licensees of the board or entity at least once annually of the  
11 opportunity to access the prescription drug pricing disclosure website.

12 The bill also requires that each pharmaceutical manufacturing  
13 company that engages in any form of prescription drug marketing,  
14 either directly or through the use of a pharmaceutical marketer, with a  
15 New Jersey practitioner, a practitioner's designee, or any member of a  
16 practitioner's staff, to provide to the board, no later than January first,  
17 April first, July first, and October first of each calendar year, the  
18 current wholesale acquisition cost information for the pharmaceutical  
19 drugs or biological products marketed in the State by that company.  
20 Any pharmaceutical manufacturing company that fails to comply  
21 with these requirements will be liable to a penalty as follows: for  
22 the first offense, not less than \$200 nor more than \$5,000; and, for  
23 the second and each succeeding offense, not less than \$1,000 nor  
24 more than \$20,000.

25 Under the bill, "wholesale acquisition cost" means the  
26 pharmaceutical manufacturing company's list price for the  
27 pharmaceutical drug or biological product to wholesalers or direct  
28 purchasers in the United States for the most recent month for which  
29 the information is available, as reported in wholesale price guides or  
30 other publications of pharmaceutical drug or biological product pricing  
31 data, not including prompt pay or other discounts, rebates, or  
32 reductions in price.

# ASSEMBLY HEALTH AND SENIOR SERVICES COMMITTEE

## STATEMENT TO

### **ASSEMBLY, No. 5449**

with committee amendments

# **STATE OF NEW JERSEY**

DATED: DECEMBER 5, 2019

The Assembly Human Services Committee reports favorably and with committee amendments Assembly Bill No. 5449.

As amended by the committee, this bill requires the New Jersey State Board of Pharmacy to establish a prescription drug pricing disclosure website. In order to make this information available for the website, the amended bill further requires certain pharmaceutical manufacturing companies to provide prescription drug price information to the board.

Under the bill as amended, the board is required to develop a prescription drug pricing disclosure website in order to make prescription drug price information available to New Jersey practitioners, who are individuals currently licensed, registered, or otherwise authorized in the State to administer or prescribe drugs in the course of professional practice. The website must have a dedicated link that is prominently displayed on the board's home page and include, at a minimum, the following data elements, separated by therapeutic category: (1) name of the product; (2) whether the drug is brand name or generic; (3) drug strength; (4) per-unit wholesale acquisition cost of the drug, provided to the board by pharmaceutical manufacturing companies as required by the bill; and (5) any disclaimers deemed appropriate by the board that are not inconsistent with State and federal law or regulations. Each State board and other entity that, under Title 45 of the Revised Statutes, regulates individuals with prescriptive authority in New Jersey is required to advise the licensees of the board or entity at least once annually of the opportunity to access the prescription drug pricing disclosure website.

The amended bill also requires that each pharmaceutical manufacturing company that engages in any form of prescription drug marketing, either directly or through the use of a pharmaceutical marketer, with a New Jersey practitioner, a practitioner's designee, or any member of a practitioner's staff, to provide to the board, no later than 30 days after the end of each quarter of the calendar year, the current wholesale acquisition cost information for the pharmaceutical drugs or biological products marketed in the State by that company. Any pharmaceutical manufacturing company that fails to comply with these requirements will be liable to a penalty as follows: for the first

offense, not less than \$200 nor more than \$5,000; and, for the second and each succeeding offense, not less than \$1,000 nor more than \$20,000.

Under the bill, "wholesale acquisition cost" means the pharmaceutical manufacturing company's list price for the pharmaceutical drug or biological product to wholesalers or direct purchasers in the United States for the most recent month for which the information is available, as reported in wholesale price guides or other publications of pharmaceutical drug or biological product pricing data, not including prompt pay or other discounts, rebates, or reductions in price.

As amended and reported by the committee, this bill is identical to Senate Bill No. 2389 (1R), which was also reported by the committee on this date.

#### COMMITTEE AMENDMENTS:

The committee amendments clarify that any additional disclaimers included by the State Board of Pharmacy on the prescription drug pricing website established under the bill are not to be inconsistent with State or federal law or regulations.

The committee amendments revise the reporting requirement for pharmaceutical manufacturers to provide that the required information is to be provided to the State Board of Pharmacy no later than 30 days after the end of each quarter of the calendar year, rather than by January 1, April 1, July 1, and October 1 of each calendar year.

**SENATE BILL NO. 2389**  
**(First Reprint)**

To the Senate:

Pursuant to Article V, Section I, Paragraph 14 of the New Jersey Constitution, I am returning Senate Bill No. 2389 (First Reprint) with my recommendations for reconsideration.

This bill requires the New Jersey State Board of Pharmacy (the "board") to establish a prescription drug pricing disclosure website for utilization by New Jersey practitioners who are currently licensed, registered, or otherwise authorized in the State to administer or prescribe drugs in the course of professional practice. To facilitate this information sharing, the bill further requires certain pharmaceutical manufacturing companies to provide prescription drug price information to the board.

I share the sponsors' desire to increase the transparency of prescription drug pricing. However, the website contemplated in this bill is more appropriately developed and maintained by the Division of Consumer Affairs (the "Division"). Since 2006, the Division has been responsible for providing consumers retail price information for the most frequently prescribed medications in the State through the New Jersey Prescription Drug Retail Price Registry, N.J.S. 45:14-81 et seq. Because the requirements of this bill dovetail with the Division's current disclosure responsibilities related to prescription drug costs, I am recommending revisions to require the Division, rather than the board, to establish and maintain the prescription drug pricing disclosure website.

Additionally, I believe the bill could be improved by setting forth a clear time frame in which to establish the disclosure website. Specifically, my recommended revisions require the Division to establish the disclosure website no later than six months after the Division has received grant funds in an amount sufficient to develop and maintain the website.

Accordingly, I herewith return Senate Bill No. 2389

(First Reprint) and recommend that it be amended as follows:

- Page 2, Title, Lines 2-3: Delete "P.L.2003, c.280 (C.45:14-40 et seq.)" and insert "P.L.2006, c.84 (C.45:14-81 et seq.)"
- Page 2, Section 1, Line 8: Delete "The New Jersey State Board of Pharmacy" and insert "As provided in subsection c. of this section, the Division of Consumer Affairs in the Department of Law and Public Safety"
- Page 2, Section 1, Line 12: Delete "board's" and insert "division's"
- Page 2, Section 1, Line 19: Delete "board" and insert "division"
- Page 2, Section 1, Line 22: Delete "board" and insert "New Jersey State Board of Pharmacy"
- Page 2, Section 1, Line 24: Delete "board" and insert "division"
- Page 2, Section 1, Line 26: Delete "board" and insert "division"
- Page 2, Section 1, Line 28: Delete "board" and insert "division"
- Page 2, Section 1, Line 30: Delete "board's" and insert "division's"
- Page 2, Section 1, Line 30: After "section." insert "The division shall establish the disclosure website no later than six months after it receives grant funds in an amount sufficient to develop and operate the website as provided in this subsection."
- Page 2, Section 2, Lines 38-39: Delete "by the New Jersey State of Board of Pharmacy"
- Page 2, Section 2, Line 45: Delete "New Jersey"
- Page 3, Section 2, Line 1: Delete "State Board of Pharmacy" and insert "Division of Consumer Affairs in the Department of Law and Public Safety"

Respectfully,

[seal]

/s/ Philip D. Murphy

Governor

Attest:

/s/ Matthew J. Platkin

Chief Counsel to the Governor

January 9, 2020

**SENATE BILL NO. 2389**  
**(First Reprint)**

To the Senate:

Pursuant to Article V, Section I, Paragraph 14 of the New Jersey Constitution, I am returning Senate Bill No. 2389 (First Reprint) with my recommendations for reconsideration.

This bill requires the New Jersey State Board of Pharmacy (the "board") to establish a prescription drug pricing disclosure website for utilization by New Jersey practitioners who are currently licensed, registered, or otherwise authorized in the State to administer or prescribe drugs in the course of professional practice. To facilitate this information sharing, the bill further requires certain pharmaceutical manufacturing companies to provide prescription drug price information to the board.

I share the sponsors' desire to increase the transparency of prescription drug pricing. However, the website contemplated in this bill is more appropriately developed and maintained by the Division of Consumer Affairs (the "Division"). Since 2006, the Division has been responsible for providing consumers retail price information for the most frequently prescribed medications in the State through the New Jersey Prescription Drug Retail Price Registry, N.J.S. 45:14-81 et seq. Because the requirements of this bill dovetail with the Division's current disclosure responsibilities related to prescription drug costs, I am recommending revisions to require the Division, rather than the board, to establish and maintain the prescription drug pricing disclosure website.

Additionally, I believe the bill could be improved by setting forth a clear time frame in which to establish the disclosure website. Specifically, my recommended revisions require the Division to establish the disclosure website no later than six months after the Division has received grant funds in an amount sufficient to develop and maintain the website.

Accordingly, I herewith return Senate Bill No. 2389 (First Reprint) and recommend that it be amended as follows:

- Page 2, Title, Lines 2-3: Delete "P.L.2003, c.280 (C.45:14-40 et seq.)" and insert "P.L.2006, c.84 (C.45:14-81 et seq.)"
- Page 2, Section 1, Line 8: Delete "The New Jersey State Board of Pharmacy" and insert "As provided in subsection c. of this section, the Division of Consumer Affairs in the Department of Law and Public Safety"
- Page 2, Section 1, Line 12: Delete "board's" and insert "division's"
- Page 2, Section 1, Line 19: Delete "board" and insert "division"
- Page 2, Section 1, Line 22: Delete "board" and insert "New Jersey State Board of Pharmacy"
- Page 2, Section 1, Line 24: Delete "board" and insert "division"
- Page 2, Section 1, Line 26: Delete "board" and insert "division"
- Page 2, Section 1, Line 28: Delete "board" and insert "division"
- Page 2, Section 1, Line 30: Delete "board's" and insert "division's"
- Page 2, Section 1, Line 30: After "section." insert "The division shall establish the disclosure website no later than six months after it receives grant funds in an amount sufficient to develop and operate the website as provided in this subsection."
- Page 2, Section 2, Lines 38-39: Delete "by the New Jersey State of Board of Pharmacy"
- Page 2, Section 2, Line 45: Delete "New Jersey"
- Page 3, Section 2, Line 1: Delete "State Board of Pharmacy" and insert "Division of Consumer Affairs in the Department of Law and Public Safety"

Respectfully,

[seal]

/s/ Philip D. Murphy

Governor

Attest:

/s/ Matthew J. Platkin

Chief Counsel to the Governor

# Governor Murphy Takes Action on Legislation

01/21/2020

**TRENTON** – Today, Governor Phil Murphy signed the following bills into law:

**S-62/A-2478 (Singleton, Oroho/DeAngelo, Houghtaling, Space)** – Requires certain contractors to register under "The Public Works Contractor Registration Act"

**S-358/A-4587 (Rice/Sumter, Reynolds-Jackson)** – Establishes database with certain information about individuals elected to public office in this State

**S-376/A-3839 (Madden, Gopal/Moriarty, Lagana, Mukherji, Murphy)** – Eliminates eligibility time limit on tuition benefits for spouses of certain public safety workers killed in performance of their duties

**S-497/A-4626 (Vitale, Madden/Mosquera, McKnight, Vainieri Huttle)** – Allows certain prior statements by children to be admitted into evidence in child abuse and termination of parental rights cases

**S-498/ACS for A-3391 (Vitale, Oroho/DeCroce, Johnson, DiMaso)** – Makes various changes to "Criminal Injuries Compensation Act of 1971"

**S-521/A-4378 (T. Kean, C.A. Brown, Pou, Ruiz/Caputo, Mukherji, Vainieri Huttle)** – Requires NJ State Council on Arts to establish "Artist District" designation and select certain municipalities or areas within municipalities for such designation

**S-589/ACS for A-422 (Weinberg/Mosquera, Jones, Moriarty)** – Requires Secretary of State to establish secure Internet website for online voter registration; authorizes use of digitized signatures from New Jersey Motor Vehicle Commission's database

**S-700/A-3836 (Ruiz, Cunningham/Schaer, Mukherji, Jasey)** – "Higher Education Citizenship Equality Act"; defines domicile for dependent students for purpose of eligibility for State student grants and scholarships, and resident tuition rate

**S-721/A-1751 (Greenstein, Cunningham, Diegnan/Quijano, Benson)** – Authorizes use of certain electric school buses

**S-758/A-1987 (Cunningham, Cruz-Perez/Sumter, Mukherji, Quijano)** – Requires incarcerated individual from State to be counted at residential address for legislative redistricting purposes

**S-765/A-541 (Cunningham, T. Kean, Ruiz/Mazzeo, Jasey, Vainieri Huttle, Sumter, Benson)** – Prohibits Higher Education Student Assistance Authority from referring defaulted loans under New Jersey College Loans to Assist State Students (NJCLASS) Loan Program for certain actions if authority and borrower have entered into settlement agreement

**S-782/A-1110 (Sarlo, Scutari/Downey, Houghtaling, Dancer)** – Increases workers' compensation for loss of hand or foot

**S-834 wGR/A-4186 (Scutari, Greenstein/Jones, Pintor Marin)** – Prohibits resale of non-prescription diabetes test devices by pharmacists

**S-939/A-3331 (Pou/Vainieri Huttle, Lopez, McKnight)** – Requires forms and materials for individuals with developmental disabilities to be available in languages other than English

**S-974/A-3040 (Singleton, T. Kean/Vainieri Huttle, Timberlake, Mosquera)** – Requires newborn infants be screened for spinal muscular atrophy



- S-1032/A-2389 (Vitale, Gopal/Schaer, Benson, Verrelli)** – Concerns expansion of services provided by DHS mental health screening services
- S-1146/A-2365 (Codey, Rice/Vainieri Huttle, Mukherji, Downey)** – Requires hospital patient's medical record to include notation if patient is at increased risk of confusion, agitation, behavioral problems, and wandering due to dementia related disorder
- S-1298/ACS for A-2972 (A.M. Bucco, Singleton/Mazzeo, Dunn, Space)** – Permits municipalities to provide information on property tax bills concerning amount of local tax dollars saved through shared services
- S-1318/A-3156 (Ruiz, Scutari/Lampitt, Mosquera)** – Permits counties and non-governmental, community-based agencies to establish family justice centers which provide coordinated, multi-agency governmental and non-governmental assistance to victims of certain crimes and offenses, including domestic violence, and their family members
- S-1505/A-1707 (Vitale/Vainieri Huttle, Lampitt, Benson, Mosquera)** – Expands membership of NJ Task Force on Child Abuse and Neglect
- S-1647/A-3181 (Diegnan, Codey/Conaway, Vainieri Huttle, Benson, Murphy)** – Prohibits use of coupons, price rebates, and price reduction promotions in sales of tobacco and vapor products
- S-1683/A-4267 (Smith, Greenstein/McKeon, Space, Wirths)** – Concerns regulation of solid waste, hazardous waste, and soil and fill recycling industries
- S-1703/A-715 (Connors, Holzapfel/Gove, Rumpf, DiMaso)** – Exempts disabled veterans from beach buggy permit fees
- S-1791/A-3414 (Weinberg/Johnson, Vainieri Huttle, Houghtaling)** – Requires employers to disclose certain wage information to employees
- S-1796/A-4693 (Addiego, Sweeney/Murphy)** – Permits school district of residence to provide aid in-lieu-of transportation to pupil attending Marine Academy of Science and Technology provided certain conditions are met
- S-1832/A-211 (Ruiz, Sarlo/Chiaravalloti, Zwicker, Pintor Marin)** – Establishes loan redemption program and tuition reimbursement program for certain teachers of science, technology, engineering, and mathematics
- S-2267/A-3616 (Sweeney, Corrado/Burzichelli, Holley, Calabrese)** – Gives State lottery winners option of remaining anonymous indefinitely
- S-2303/A-4843 (Sweeney, Ruiz, Cunningham/Wimberly, Karabinchak, Calabrese)** – Requires establishment of Work and Learn Consortiums by certain educational institutions to establish certificate and degree programs identified in high labor-demand industries
- S-2389 wGR/A-5449 (Singleton/Quijano, Downey, Houghtaling, Moriarty)** – Requires New Jersey State Board of Pharmacy to establish prescription drug pricing disclosure website and certain pharmaceutical manufacturing companies to provide prescription drug price information
- S-2428/A-4965 (Scutari/Quijano, Vainieri Huttle)** – Requires that massage and bodywork therapists and employers carry professional liability insurance
- S-2469/A-3745 (Singleton, Oroho/Wirths, Mazzeo, Space)** – Prohibits person from contracting for public work if person is federally debarred from receiving federal contract
- S-2511/A-4020 (Madden/Mazzeo, Murphy, Johnson)** – Changes title of DEP "conservation officer" to "conservation police officer"
- S-2521/A-4087 (Cryan, Greenstein/Vainieri Huttle, Lopez, Timberlake)** – Requires reporting of inmate abuse by employees of State correctional facilities and establishes reporting and investigation program
- S-2522/A-4090 (Cryan, Greenstein/Vainieri Huttle, Lopez, Timberlake)** – Limits cross gender strip searches in

## State correctional facilities

**S-2532/A-4086 (Greenstein, Cruz-Perez/Vainieri Huttle, Lopez, Timberlake)** – Requires correctional police officers receive 20 hours in-service training, including four hours in prevention of sexual misconduct, non-fraternization, and manipulation

**S-2555/A-3990 (Gopal, Ruiz/Mukherji, Benson, Karabinchak)** – Allows dependent students whose parents or guardians hold H-1B visas to qualify for in-State tuition at public institutions of higher education provided they meet certain criteria

**S-2564/A-3519 (Turner, Singleton/Benson, McKnight, Jasey)** – Establishes "Restorative Justice in Education Pilot Program" in Department of Education

**SCS for S-2599/ACS for A-1268 (Bateman, Beach/Tucker, Conaway, Lampitt, Quijano)** – Authorizes veterans' property tax exemption and veterans' property tax deduction for honorably discharged veterans of United States Armed Forces who did not serve in time of war or other emergency

**S-2826/A-3274 (Greenstein/Vainieri Huttle, Dancer, Benson)** – Requires institutions of higher education to offer cats and dogs no longer used for educational, research, or scientific purposes for adoption; designated the "Homes for Animal Heroes Act"

**S-2849/A-4590 (A.M. Bucco/DiMaio, Caputo, Dunn)** – Designates Seeing Eye® dog as State Dog

**S-3036/A-1697 (Lagana, Scutari/Dancer, Downey)** – Prohibits medical providers from reporting certain workers' compensation medical charges to collection and credit reporting agencies

**S-3061/A-4603 (Ruiz, Greenstein/Lampitt, Mukherji, Benson)** – Provides corporation business tax and gross income tax credits for businesses that participate in DOL registered apprenticeship programs; establishes grant program for tax-exempt organizations participating in DOL registered apprenticeship programs

**S-3065/A-4657 (Ruiz, Singleton/Armato, Benson, Timberlake)** – Establishes youth apprenticeship pilot program in Department of Education

**S-3067/A-4602 (Ruiz, Singleton/Lampitt, Reynolds-Jackson, Sumter)** – Establishes five year Apprentice Assistance and Support Services Pilot Program

**S-3116/A-4683 (Ruiz/Speight, Munoz, Tucker)** – Requires certain medical facilities to undertake end-of-life planning and training

**S-3117/A-4685 (Ruiz/Speight, Pinkin, Munoz)** – Requires emergency departments to take certain measures concerning palliative care for patients

**S-3126/A-4107 (Gopal/Benson, DeCroce, Chiaravalloti)** – Requires drivers to stop at railroad crossing when on-track equipment is approaching railroad crossing

**S-3170/A-5145 (Cryan, Pou/Quijano, Milam, Land)** – Increases prenotification time and requires severance pay in certain plant closings, transfers, and mass layoffs

**S-3227/A-5261 (Gopal/Tully, Pinkin, Swain)** – Requires restaurants to post signs advising customers to notify servers of food allergies; requires restaurant managers to complete food allergen training

**S-3265/A-3178 (Turner, Codey, Vitale/Conaway, Murphy, Vainieri Huttle)** – Prohibits sale or distribution of flavored vapor products

[Copy of Statement](#)

**S-3330 wGR/A-5066 (Addiego, Singleton/Jones, Vainieri Huttle, Lampitt, Murphy)** – Establishes pilot program in DCF to study impact of child care services provided by community providers operating in public school facilities; requires community providers to meet certain criteria

**S-3422/A-6056 (Singer, T. Kean/Houghtaling, Downey, Vainieri Huttle)** – Requires declaration of Code Blue

alert when National Weather Service predicts temperatures of 32 degrees Fahrenheit or lower

**S-3468/A-5105 (Sweeney, Singleton/Murphy, Karabinchak, Vainieri Huttle)** – Establishes Task Force on Maximizing Employment for People with Disabilities

**S-3511/A-5298 (Singer, T. Kean/Mukherji, Vainieri Huttle, Downey)** – Authorizes certain health care and social service resources to be made available during Code Blue alert

**S-3581/A-5963 (Singleton/Lopez, Quijano)** – Prohibits certain business financing contracts that contain judgment by confession provisions

**S-3685/A-5345 (Sarlo, Singleton/Mukherji, Conaway, McKnight)** – Establishes program to increase participation of underrepresented students in New Jersey's science and engineering workforce

**S-3756/A-6115 (Ruiz, Sarlo, O'Scanlon/Jasey, Jones, Wirths)** – Requires limited purpose regional school districts to coordinate with constituent districts regarding school calendar and curriculum

**S-3763/A-6116 (Addiego, Bateman, Sarlo/DeAngelo, Dancer, Space)** – Renames joint meetings as regional service agencies; grandfathers existing joint meetings

**S-3869/A-5561 (Sarlo/Burzichelli, Houghtaling)** – Prohibits local governments from imposing fines on alarm companies in certain circumstances

**S-3871/A-5427 (Bateman, Scutari/DePhillips, McKeon)** – Adds member from Retired Judges Association of New Jersey to State Investment Council

**SCS for S-3878/ACS for A-5394 (Ruiz, Weinberg, Cunningham/Moriarty, McKnight, Pinkin)** – Reaffirms and clarifies that Attorney General and Division on Civil Rights may initiate actions in Superior Court to enforce "Law Against Discrimination"

**S-3920 wGR/A-5552 (Pou/Wimberly, Sumter)** – Concerns provision of energy to certain manufacturing facilities by providing exemptions to certain energy related taxes

**S-3923/A-5680 (Madden, Singleton/Giblin, Timberlake, Murphy)** – Concerns labor harmony agreements for hospitality projects

**SCS for S-3939 and 3944/ACS for A-5681 and 5682 (Smith, Greenstein, Bateman, Codey/Pinkin, Lopez, McKeon)** – Establishes Recycling Market Development Council

**S-3985/A-5663 (Smith/McKeon, Pinkin, Vainieri Huttle)** – Amends "Electric Discount and Energy Competition Act" to add definition of "open access offshore wind transmission facility" and revises law concerning "qualified offshore wind projects"

**S-4025/A-5695 (Pou/Wimberly, Sumter)** – Makes FY 2020 language allocation of \$1,000,000 appropriated to Grants for Urban Parks to Hinchliffe Stadium in Paterson

**S-4162/A-6014 (Smith, Greenstein/Vainieri Huttle, Pinkin, Houghtaling)** – Establishes NJ Climate Change Resource Center at Rutgers University; appropriates up to \$500,000

**S-4165/A-4364 (Rice/Giblin, Caputo, Tucker)** – Expands University Hospital board of directors membership from 11 to 13 members

**S-4188/A-6075 (Beach/Murphy, Dancer, Lampitt)** – "Lindsay's Law"; provides tax benefits to organ and bone marrow donors and their employers, and provides paid time off to donors who are State or local government employees

**S-4200/A-5855 (Ruiz, Turner/Coughlin, Lampitt, Holley)** – Requires State to pay difference between federal allocation and total cost of reduced price breakfast or lunch; appropriates \$4.5 million

**S-4247/A-6049 (Gopal, O'Scanlon/Conaway, Houghtaling, Downey)** – Establishes criteria for distribution of Fiscal Year 2020 funding to Community Food Bank of New Jersey and partner organizations

**S-4264/A-5962 (Pou/Wimberly, Sumter, Calabrese)** – Designates State Highway Route 19 as "William J. Pascrell Jr. Highway"

**S-4275/A-6088 (Smith, Greenstein/Burzichelli)** – Allows BPU to increase cost to customers of Class I renewable energy requirement for energy years 2022 through 2024, under certain conditions

**S-4276/A-6109 (Corrado, Bateman/Armato, Calabrese, Land)** – Appropriates \$32,153,936 to State Agriculture Development Committee, and amends 2017 appropriations for stewardship activities, for farmland preservation purposes

**S-4277/A-6112 (Greenstein, Bateman/Freiman, Danielsen, Downey)** – Appropriates \$5,000,000 from constitutionally dedicated CBT revenues to State Agriculture Development Committee for municipal planning incentive grants for farmland preservation purposes

**S-4278/A-6108 (Greenstein, Bateman/Taliaferro, Karabinchak, Kennedy)** – Appropriates \$21 million from constitutionally dedicated CBT revenues to State Agriculture Development Committee for county planning incentive grants for farmland preservation purposes

**S-4279/A-6106 (Smith, Bateman/Houghtaling, Reynolds-Jackson, Pinkin)** – Appropriates \$1,350,000 from constitutionally dedicated CBT revenues to State Agriculture Development Committee for grants to certain nonprofit organizations for farmland preservation purposes

**S-4286/A-5890 (Vitale/Swain, Jones)** – Clarifies procedures concerning collection of child support on behalf of child over age 19 when court has ordered such support

**S-4309/A-6107 (Turner, Cruz-Perez/Mejia, Vainieri Huttie, Zwicker)** – Appropriates \$13,902,723 from constitutionally dedicated CBT revenues to NJ Historic Trust for grants for certain historic preservation projects and associated administrative expenses

**S-4310/A-6114 (Codey, Bateman/Carter, Murphy, Lopez)** – Appropriates \$8,872,682 to DEP from constitutionally dedicated CBT revenues for grants to certain nonprofit entities to acquire or develop lands for recreation and conservation purposes

**S-4311/A-6113 (Greenstein, Bateman/Speight, Mukherji, Verrelli)** – Appropriates \$77,450,448 from constitutionally dedicated CBT revenues and various Green Acres funds to DEP for local government open space acquisition and park development projects

**S-4312/A-6111 (Smith, Bateman/Giblin, Mazzeo, Land)** – Appropriates \$36.143 million from constitutionally dedicated CBT revenues for recreation and conservation purposes to DEP for State capital and park development projects

**S-4313/A-6110 (Corrado, Bateman/Moriarty, McKeon, Swain)** – Appropriates \$33.915 million from constitutionally dedicated CBT revenues to DEP for State acquisition of lands for recreation and conservation purposes, including Blue Acres projects

**SCS for S-4315/ACS for A-6063 (Beach, Turner/Jones, Zwicker)** – Creates fund to reimburse local units of government for cost of certain mail-in ballot procedures; appropriates \$3,000,000

**SJR-51/AJR-189 (Rice, Turner/Verrelli, Reynolds-Jackson, Sumter)** – Establishes the "New Jersey State Commission on Urban Violence"

**SJR-65/AJR-90 (Weinberg, Addiego/DiMaso, Vainieri Huttie, Schepisi)** – Designates March 19th "Women in Public Office Day" in New Jersey

**SJR-80/AJR-121 (Lagana, Weinberg/Jones, Benson, Chiaravalloti, DeCroce)** – Urges federal government to adhere to commitment to improve Northeast Corridor rail infrastructure by providing funding to complete Gateway Program

**SJR-125/AJR-169 (Gopal, Codey/Wolfe, Pinkin)** – Designates the second week of October of each year as "Obesity Care Week" in NJ

- A-344/S-1575 (Murphy, McKeon, Timberlake/Cruz-Perez, Singleton)** – Revises certain aspects of the New Jersey Individual Development Account Program
- A-1040/S-3928 (Houghtaling, Taliaferro/Andrzejczak)** – Establishes NJ "Landowner of the Year" award program
- A-1146/S-4330 (Wimberly, Holley/Pou, Singleton)** – Establishes "New Jersey Investing in You Promise Neighborhood Commission"
- A-1277/S-2629 (Tucker, Holley, Lopez/Singleton, Gopal)** – Requires hospitals and homeless shelters to provide information on services and resources to individuals who are homeless or military veterans
- A-1449/S-3168 (Benson, DeAngelo/Greenstein, Turner)** – Provides job security to certain organ and bone marrow donors
- A-1477/S-3228 (Chaparro, Vainieri Huttle, Benson, Jimenez, Mukherji, Downey/Gopal, Scutari)** – Establishes Statewide Hit and Run Advisory Program to facilitate apprehension of persons fleeing motor vehicle accident scene; designated as "Zackhary's Law"
- A-1478/S-1648 (Chaparro, Vainieri Huttle/Diegnan, T. Kean)** – Revises law governing theater liquor licenses
- A-1604/S-2734 (Conaway, Murphy, Jimenez/Singleton)** – "Recreational Therapists Licensing Act"
- A-1796/S-2609 (McKeon, Downey/Lagana, Gopal)** – Prevents criminal defendant from asserting "gay and transgender panic" defense to murder charge in order to reduce charge to manslaughter committed in heat of passion
- A-1924/S-2930 (Mukherji, A.M. Bucco, DeAngelo, DeCroce/Beach)** – Exempts certain honorably discharged United States military veterans from initial insurance producer licensing fee
- A-1992/S-1780 (Sumter, Benson, Vainieri Huttle, Houghtaling, Wimberly/Diegnan, Turner)** – "New Jersey Call Center Jobs Act"
- A-2183/S-1687 (Land, Johnson/Cruz-Perez, Andrzejczak)** – "Music Therapist Licensing Act"
- ACS for A-2431 wGR/SCS for S-1865 (Benson, Jimenez, DeCroce/Weinberg, T. Kean)** – Requires health insurers to provide plans that limit patient cost-sharing concerning certain prescription drug coverage
- ACS for A-2444 and S-2656/S-2081 (Benson, Lampitt, Pinkin, Mukherji/Turner, Singleton)** – Provides for coverage of comprehensive tobacco cessation benefits in Medicaid
- A-2767/S-2924 (Greenwald, Mosquera, McKnight/Greenstein, Singleton)** – Amends certain provisions of sexual assault statute to clarify elements necessary for conviction
- A-3312/S-1972 (Murphy, Lagana, Downey, Sumter/Gopal, Corrado)** – Requires Legislature to adopt and distribute policy prohibiting sexual harassment; requires members, officers, and employees of Legislature to complete online training on policy once every two years
- A-3670/S-995 (Benson, Giblin, Murphy/Vitale, Weinberg)** – Provides for designation of acute stroke ready hospitals, establishes Stroke Care Advisory Panel and Statewide stroke database, and requires development of emergency medical services stroke care protocols
- ACS for A-4136/SCS for S-2675 (Land, Milam/Andrzejczak, Van Drew)** – Establishes Possession In Excess of Daily Limit Vessel License for black sea bass and summer flounder; dedicates fees therefrom to marine fisheries programs
- A-4147/S-2744 (Lampitt, Houghtaling, Zwicker/Ruiz, Corrado)** – Requires school districts and nonpublic schools to conduct audit of security features of buildings, grounds, and communication systems and to submit audit to NJ Office of Homeland Security and Preparedness and DOE

- A-4150/S-2742 (Lampitt, Jones, Timberlake/Ruiz, Corrado)** – Requires meeting between student and appropriate school personnel after multiple suspensions or proposed expulsion from public school to identify behavior or health difficulties
- A-4151/S-2745 (Swain, Tully, Jasey/Ruiz, Corrado)** – Requires school security training for persons employed by public and nonpublic schools in substitute capacity and for employees and volunteers of youth programs operated in school buildings
- A-4260/S-4335 (Timberlake, Giblin, Tucker, Caputo/Pou, Scutari)** – Prohibits sale of certain toy guns and imitation firearms
- A-4370/S-2919 (Carroll/A.M. Bucco)** – Increases membership of board of trustees of Washington Association of New Jersey
- A-4377/S-2934 (Benson, Land, DeCroce/Greenstein)** – Requires DOT and OIT to develop materials concerning capabilities of airports in NJ and establishes "Public Use Airports Task Force"
- A-4517/S-4341 (Wimberly, Speight, Reynolds-Jackson/Singleton, Cunningham)** – Establishes "New Jersey Eviction Crisis Task Force"
- A-4529/S-3191 (Mazzeo, Armato/Gopal, Andrezejczak)** – Concerns reimbursements to Superstorm Sandy-impacted homeowners subjected to contractor fraud
- A-4563/S-3096 (Zwicker, Benson/Greenstein, Gill)** – Prohibits use of bots to deceive person about origin and content of communication for certain commercial or election purposes
- A-4564/S-3087 (Zwicker, Freiman/Greenstein)** – Establishes "Voting Precinct Transparency Act;" requires filing of election district, county district, and municipal ward boundary data with Secretary of State for posting and download on official website with matching election results data
- A-4699/S-2938 (Moriarty, Burzichelli, Bramnick/Turner)** – Regulates annual report filing services
- A-4803/S-4211 (Greenwald, Johnson, Pintor Marin/Cryan, Vitale)** – Authorizes certain entities to directly bill Victims of Crime Compensation Office for counseling services provided to victims of firearm and stabbing crimes
- A-4822/S-3408 (Wimberly, Tully, Swain/Singleton, Greenstein)** – Permits municipalities to lease vacant municipal land for tiny home occupancy; directs DCA to enhance regulatory guidance on acceptable tiny home construction and use
- A-4904 wGR/S-3347 (Mukherji, Quijano, Mazzeo/Cryan, Sweeney)** – Concerns property taxes due and owing on real property owned by certain federal employees or contractors under certain circumstances
- A-4954/S-3368 (Quijano, Murphy, Carter/Singleton, Greenstein)** – Revises requirements for provision of counseling and support services to emergency services personnel
- ACS for A-4972/SCS for S-1490 (Moriarty/Beach, Scutari)** – Establishes certain consumer protections related to arbitration organizations
- A-4978 wGR/S-3498 (Timberlake, Zwicker, Vainieri Huttle/Greenstein, Cryan)** – Prohibits online education services from using and disclosing certain information, engaging in targeted advertising, and requires deletion of certain information in certain circumstances
- A-5023/S-3467 (McKnight, Mukherji, Chaparro, Chiaravalloti/Cunningham)** – Exempts from DOT permitting requirements certain signs not located in protected areas that have been approved by municipality
- A-5028/S-3523 (Mukherji, Conaway, Pintor Marin/Vitale, Diegnan)** – Establishes "James Nicholas Rentas's Law," revises "New Jersey SmokeFree Air Act"
- A-5029/S-3522 (Sumter, Reynolds-Jackson, Johnson/Rice, T. Kean)** – Requires New Jersey Office on Minority and Multicultural Health to study racial disparities on sexual and reproductive health of African-American women

**A-5031/S-3455 (Speight, McKnight, Timberlake/Ruiz)** – Requires hospital emergency departments to ask person of childbearing age about recent pregnancy history

**A-5314/S-3692 (Zwicker, Milam, Mazzeo/Cryan, Ruiz)** – Requires DHS to study social isolation occurring in certain population groups

**A-5344/S-3833 (Mukherji, Vainieri Huttel, Milam/Gopal, Corrado)** – Establishes uniform standard for acceptable proof of veteran status for veteran's ID cards and various State and local programs

**A-5388/S-3895 (Speight, Pintor Marin, Greenwald/Greenstein, Ruiz)** – Requires specialized in-service training regarding crime victims for police departments in certain high-crime areas

**A-5389/S-3896 (Speight, Pintor Marin, Greenwald/Greenstein, Ruiz)** – Requires training or experience in crime victims' rights for certain members of Victims of Crime Compensation Review Board

**A-5432/S-3796 (Milam, Land/Andrzejczak)** – Requires DEP Commissioner to establish individual transferable quota system for menhaden purse seine fishery

**A-5445/S-3909 (Swain, Tully, Spearman/T. Kean, Corrado)** – Requires AG to establish program to detect fentanyl in State's illegal drug supply and make information related to presence of fentanyl available in database accessible by law enforcement

**A-5511/S-1852 (Spearman, Jones, Reynolds-Jackson/Turner, Cruz-Perez)** – Revises certain penalties for illegal operation of snowmobile, all-terrain vehicle, or dirt bike

**A-5580/S-3842 (Johnson, Moriarty, Greenwald/Weinberg, Sarlo)** – Extends availability period for tax credits for certain expenses incurred for production of certain film and digital media content, raises annual cap related to film production, and provides for annual administration of film tax credits

**A-5583/S-3919 (Pinkin, Lopez, Mukherji/Smith, Bateman)** – Prohibits sale, lease, rent, or installation of certain equipment or products containing hydrofluorocarbons or other greenhouse gases

**A-5630/S-3981 (Pintor Marin, Munoz, Reynolds-Jackson/Weinberg, Corrado)** – Requires Civil Service Commission to establish and maintain hotline for State employees to submit reports of workplace discrimination and harassment

#### [Copy of Statement](#)

**A-5667/S-3933 (Mukherji, Vainieri Huttel, Armato, DeCroce, Karabinchak/Singer, Scutari)** – "Charlie's Law"; requires pharmacy practice sites and hospice programs to furnish patients with information and means to safely dispose of unused prescription drugs and medications

**A-5801/S-4064 (Coughlin, Houghtaling, Verrelli/Singleton, Sweeney)** – Concerns responsibility of contractors for wage claims against subcontractors

**A-5817/S-4263 (Mazzeo, Armato/Cunningham, Sweeney, C.A. Brown)** – Allows certain persons to qualify for casino key employee license and casino employee registration

**A-5916/S-4255 (Chiaravalloti, McKnight, Karabinchak/Cunningham, Weinberg)** – Authorizes DOH to notify elected officials of financial distress of certain hospitals

**A-5918/SCS for S-3741 and 4253 (Chiaravalloti, McKnight/Weinberg, Cunningham, Vitale)** – Expands hospital reporting requirements

**A-5970/S-4201 (Lopez, Speight, Chaparro/Codey)** – Amends list of environmental infrastructure projects approved for long-term funding for FY2020 to include new projects, remove certain projects, and modify estimated loan amounts for certain projects

**A-5971/S-4202 (Mukherji, Pintor Marin, Spearman/Bateman, Corrado)** – Authorizes NJ Infrastructure Bank to expend additional sums to make loans for environmental infrastructure projects for FY2020

**A-5972/S-4203 (Pinkin, Benson, Zwicker/Greenstein, Singleton)** – Makes changes to New Jersey Infrastructure Bank's enabling act

**A-5977/S-4282 (Greenwald, Downey, Vainieri Huttie/Vitale, Singleton)** – Provides for establishment of Regional Health Hub Program as replacement to Accountable Care Organization Demonstration Project, and designates existing accountable care organizations and look-alike organizations as Regional Health Hubs

**A-6119/S-4336 (Egan, Houghtaling/Madden)** – Revises "The Public Works Contractor Registration Act" and amends definition of registered apprenticeship program

**AJR-35/SJR-159 (McKnight, Chaparro, Chiaravalloti, DeCroce/Cunningham, Greenstein)** – Designates third full week in March as "Domestic Violence Services Awareness Week" to bring awareness of services available to domestic violence victims

**AJR-103/SJR-70 (Rooney, DePhillips, Murphy/Corrado)** – Permanently designates January as "NUT Carcinoma Awareness Month" in New Jersey

**AJR-118/SJR-157 (McKnight, Timberlake, McKeon/Pou, Madden)** – Designates April of each year as "Financial Literacy Month" in New Jersey

**AJR-180/SJR-112 (DeAngelo, McKnight, Murphy/Singleton, Corrado)** – Designates February in each year as "Career and Technical Education Month" in New Jersey

**Governor Murphy declined to sign the following bills, meaning they expire without becoming law:**

**S-691/A-657 (Ruiz, Pou/Jasey, Caputo, Pintor Marin, Sumter, Wimberly)** – Requires that if a school district satisfies 80% or more of the required NJ Quality Single Accountability Continuum standards in an area of district effectiveness under State intervention, the State must return that area to local control

**S-1083/A-544 (Cruz-Perez, Gopal/Mazzeo, Houghtaling, Holley, Dancer)** – Establishes loan program and provides corporation business tax and gross income tax credits for establishment of new vineyards and wineries

**S-2421/A-1030 (Smith, Bateman/Johnson, Kennedy, Benson, DeAngelo)** – Concerns installation of electric vehicle charging stations in common interest communities

**S-2425/A-3851 (Singleton, Andrzejczak/Conaway)** – Revises law relating to common interest communities

**S-2429/A-4028 (Scutari, Pou/Bramnick, Downey)** – Requires automobile insurers to disclose policy limits upon request by an attorney under certain circumstances

**S-2835/A-3926 (Singleton, Ruiz/Conaway, Lampitt, Murphy)** – Requires public schools to administer written screenings for depression for students in certain grades

**S-2897/A-1433 (Madden, Singer/Benson, Wimberly, Carter)** – Requires DCA to establish procedures for inspection and abatement of mold hazards in residential buildings and school facilities, and certification programs for mold inspectors and mold hazard abatement workers

**S-2957/A-4712 (Stack/Mukherji, Chaparro)** – Establishes five-year moratorium on conversions of certain residential rental premises in qualified counties

**S-2958/A-4535 (Sarlo, Oroho/Zwicker, DePhillips, DeCroce)** – Establishes the "Energy Infrastructure Public-Private Partnership Act"

**S-3062/A-2049 (Ruiz, Greenstein/Howarth, Benson, Murphy)** – Provides corporation business tax and gross income tax credits for businesses that employ apprentices in DOL registered apprenticeships

**S-3063/A-4655 (Ruiz/Armato, Vainieri Huttie, DeAngelo)** – Provides tuition fee waiver apprenticeship courses



**S-3137/A-1308 (Sweeney, Oroho, Singleton/Greenwald, Milam, Land)** – The "Electronic Construction Procurement Act"

**S-3252/A-4713 (Greenstein, Stack/DeAngelo, Quijano)** – "New Townhouse Fire Safety Act"; requires automatic fire sprinkler systems in new townhomes

**S-3263/A-4837 (T. Kean, Diegnan/Vainieri Huttle, Chiaravalloti, McKnight)** – Revises and updates membership and purpose of Advisory Council on the Deaf and Hard of Hearing in DHS

**S-3270/A-5095 (Pou/McKeon, Freiman, DeCroce)** – Establishes certain requirements for stop loss insurance offered to small employers

**S-3393/ACS for A-5384 and 5157 (Sarlo, Addiego/Mazzeo, Murphy, Houghtaling, Calabrese, Armato, Dancer)** – Allows certain preserved farms to hold 14 special occasion events per year; imposes further event restrictions on residentially-exposed preserved farms

**S-3770/A-6118 (Sarlo, Oroho, Sweeney/Greenwald, Jones)** – Establishes "New Jersey Economic and Fiscal Policy Review Commission" to provide ongoing review of State and local tax structure, economic conditions, and related fiscal issues

**S-3888/A-5585 (Ruiz/Dancer, Pintor Marin)** – Extends document submission deadlines under Economic Redevelopment and Growth Grant program and Urban Transit Hub Tax Credit program

**S-4035/A-5702 (Pou, Singleton/Wimberly, Reynolds-Jackson, Sumter)** – Makes Fiscal Year 2020 supplemental appropriation of \$1,700,000 for Thomas Edison State University

**S-4281/A-6094 (Smith, Diegnan/Danielsen, Pinkin)** – Requires State to sell and convey to Educational Services Commission of New Jersey certain land and improvements known as Piscataway Regional Day School

**S-4331/A-4727 (Diegnan, Madden/Karabinchak, Holley, Jones)** – Requires person taking written examination for permit to watch video of rights and responsibilities of driver stopped by law enforcement; requires testing on rights and responsibilities of driver stopped by law enforcement

**A-491/S-4340 (Jimenez/Sacco, Stack)** – Enhances PFRS accidental death pension for surviving spouse by providing for minimum of \$50,000 annually

**A-1044/S-1441 (Houghtaling, Downey, DiMaio, Space/Doherty, Madden)** – Requires Director of Division of Taxation to examine feasibility of centralized property tax information system to verify property taxes paid by homestead property tax reimbursement claimants

**A-1045/S-2856 (Houghtaling, Downey, Dancer/Gopal, Oroho)** – Clarifies sales tax collection responsibilities of horse-boarding businesses in New Jersey

**A-1526/S-1048 (Zwicker, Johnson/Vitale)** – Concerns payment of independent contractors

**A-2731/S-3407 (Taliaferro, Space/Sweeney, Oroho)** – Removes statutory limitation on number of permits that may be issued by Division of Fish and Wildlife for the taking of beaver

**A-4382/S-2815 (Pinkin, Lopez, Kennedy/Beach, Smith)** – Requires paint producers to implement or participate in paint stewardship program

**A-4463/S-3927 (Freiman, Egan, Karabinchak/Oroho, Andrzejczak)** – Establishes "Electronic Permit Processing Review System"

**A-4788/S-3880 (Karabinchak, Freiman, Calabrese/Diegnan)** – Establishes expedited construction inspection program

**A-5072/S-3496 (Karabinchak, Johnson, Mukherji/Greenstein, Cryan)** – "Defense Against Porch Pirates Act"; creates new category of theft, with penalties including mandatory restitution and community service, for taking package delivered to residence by cargo carrier

**A-5446/S-3907 (Land, Reynolds-Jackson, Verrelli/T. Kean, Lagana)** – Requires reporting of opioid deaths

**A-5629/S-3980 (Pintor Marin, Munoz/Weinberg, Corrado)** – Clarifies provisions concerning disclosure of existence and content of discrimination or harassment complaints; requires certain disclosures to person against whom complaint is made

[Copy of Statement](#)

**ACS for A-5922 and 5923/SCS for S-4223 and 4224 (Conaway, Vainieri Huttle, Lopez, Pinkin/Vitale, Sweeney)** – Revises requirements for sale of tobacco and vapor products; increases penalties for prohibited sales; increases fees for cigarette and vapor business licensure

[Copy of Statement](#)

§1 - C.45:14-82.1  
Title 24.  
Subtitle 1.  
Chapter 6N.  
Drug Pricing  
§2 - C.24:6N-1

P.L. 2019, CHAPTER 404, *approved January 21, 2020*  
Senate, No. 2389 (*Second Reprint*)

1 AN ACT concerning the disclosure of prescription drug price  
2 information and supplementing <sup>2</sup>[P.L.2003, c.280 (C.45:14-  
3 40 et seq.)] P.L.2006, c.84 (C.45:14-81 et seq.)<sup>2</sup> and Title 24 of  
4 the Revised Statutes.

5  
6 **BE IT ENACTED** by the Senate and General Assembly of the State  
7 of New Jersey:

8  
9 1. a. <sup>2</sup>[The New Jersey State Board of Pharmacy] As provided  
10 in subsection c. of this section, the Division of Consumer Affairs in  
11 the Department of Law and Public Safety<sup>2</sup> shall develop a  
12 prescription drug pricing disclosure website in order to make  
13 prescription drug price information available to New Jersey  
14 practitioners. The website shall have a dedicated link that is  
15 prominently displayed on the <sup>2</sup>[board's] division's<sup>2</sup> home page.

16 b. The website shall include, at a minimum, the following data  
17 elements, separated by therapeutic category:

18 (1) name of the product;

19 (2) whether the drug is brand name or generic;

20 (3) drug strength;

21 (4) per-unit wholesale acquisition cost of the drug, provided to  
22 the <sup>2</sup>[board] division<sup>2</sup> by pharmaceutical manufacturing companies  
23 pursuant to section 2 of P.L. , c. (C. ) (pending before the  
24 Legislature as this bill); and

25 (5) any disclaimers deemed appropriate by the <sup>2</sup>[board]  
26 division<sup>2</sup> <sup>1</sup>that are not inconsistent with State or federal law or  
27 regulations<sup>1</sup> .

28 c. The <sup>2</sup>[board] division<sup>2</sup> shall actively seek grant funds to  
29 implement the provisions of this section, and implementation shall  
30 be contingent upon the <sup>2</sup>[board] division<sup>2</sup> obtaining sufficient grant  
31 funds for the development, operation, and continued maintenance of  
32 the prescription drug pricing disclosure website. The <sup>2</sup>[board]

**EXPLANATION** – Matter enclosed in bold-faced brackets **[thus]** in the above bill is not enacted and is intended to be omitted in the law.

Matter underlined thus is new matter.

Matter enclosed in superscript numerals has been adopted as follows:

<sup>1</sup>Senate SHH committee amendments adopted June 3, 2019.

<sup>2</sup>Senate amendments adopted in accordance with Governor's recommendations January 13, 2020.

1 division<sup>2</sup> shall have the authority to enter into a contract for the  
2 administration of the <sup>2</sup>**board's** division's<sup>2</sup> responsibilities  
3 pursuant to this section. <sup>2</sup>The division shall establish the disclosure  
4 website no later than six months after it receives grant funds in an  
5 amount sufficient to develop and operate the website as provided in  
6 this subsection.<sup>2</sup>

7 d. Each State board and other entity that, under Title 45 of the  
8 Revised Statutes, regulates individuals with prescriptive authority in  
9 New Jersey shall advise the licensees of the board or entity at least  
10 once annually of the opportunity to access the prescription drug  
11 pricing disclosure website.

12  
13 2. a. For the purposes of the prescription drug pricing  
14 disclosure website required <sup>2</sup>**by the New Jersey State Board of**  
15 **Pharmacy**<sup>2</sup> pursuant to section 1 of P.L. , c. (C. ) (pending  
16 before the Legislature as this bill), each pharmaceutical  
17 manufacturing company that engages in prescription drug  
18 marketing, either directly or through the use of a pharmaceutical  
19 marketer, with a New Jersey practitioner as defined in section 2 of  
20 P.L.2003, c.280 (C.45:14-41), a practitioner's designee, or any  
21 member of a practitioner's staff, shall provide to the <sup>2</sup>**New Jersey**  
22 **State Board of Pharmacy** Division of Consumer Affairs in the  
23 Department of Law and Public Safety<sup>2</sup>, no later than <sup>1</sup>**January**  
24 **first, April first, July first, and October first** 30 days after the end<sup>1</sup>  
25 of each <sup>1</sup>quarter of the<sup>1</sup> calendar year, the current wholesale  
26 acquisition cost information for the pharmaceutical drugs or  
27 biological products marketed in the State by that company.

28 b. The provisions of this section shall only apply to  
29 prescription drug marketing engaged in by a pharmaceutical  
30 manufacturing company and a practitioner, a practitioner's  
31 designee, or any member of a practitioner's staff, while physically  
32 present in the state of New Jersey.

33 c. Any pharmaceutical manufacturing company that fails to  
34 comply with the requirements of this section shall be liable to a  
35 penalty as follows: for the first offense, not less than \$200 nor  
36 more than \$5,000; and, for the second and each succeeding offense,  
37 not less than \$1,000 nor more than \$20,000. The penalties shall be  
38 enforced by the Director of Consumer Affairs in the Department of  
39 Law and Public Safety in a summary proceeding in accordance with  
40 the "Penalty Enforcement Law of 1999," P.L.1999, c.274 (C.2A:58-  
41 10 et seq.).

42 d. For purposes of this section:

43 "Pharmaceutical marketer" means a person who, while employed  
44 by or under contract to represent a pharmaceutical manufacturing  
45 company, engages in prescription drug marketing activities.

1 "Prescription drug marketing" means any activity, including, but  
2 not limited to, in-person meetings, physical mailings, telephonic  
3 conversations, video conferencing, electronic mail, or facsimile,  
4 that provides educational or marketing information or materials  
5 regarding a prescription drug.

6 "Wholesale acquisition cost" means the pharmaceutical  
7 manufacturing company's list price for the pharmaceutical drug or  
8 biological product to wholesalers or direct purchasers in the United  
9 States for the most recent month for which the information is  
10 available, as reported in wholesale price guides or other  
11 publications of pharmaceutical drug or biological product pricing  
12 data, not including prompt pay or other discounts, rebates, or  
13 reductions in price.

14

15 3. This act shall take effect immediately.

16

17

18

19

20 \_\_\_\_\_  
21 Requires New Jersey State Board of Pharmacy to establish  
22 prescription drug pricing disclosure website and certain  
23 pharmaceutical manufacturing companies to provide prescription  
drug price information.

**SENATE, No. 2389**

---

**STATE OF NEW JERSEY**  
**218th LEGISLATURE**

---

INTRODUCED APRIL 5, 2018

**Sponsored by:**  
**Senator TROY SINGLETON**  
**District 7 (Burlington)**

**SYNOPSIS**

Requires New Jersey State Board of Pharmacy to establish prescription drug pricing disclosure website and certain pharmaceutical manufacturing companies to provide prescription drug price information.

**CURRENT VERSION OF TEXT**

As introduced.



1 AN ACT concerning the disclosure of prescription drug price  
2 information and supplementing P.L.2003, c.280 (C.45:14-40 et  
3 seq.) and Title 24 of the Revised Statutes.

4  
5 **BE IT ENACTED** by the Senate and General Assembly of the State  
6 of New Jersey:

7  
8 1. a. The New Jersey State Board of Pharmacy shall develop a  
9 prescription drug pricing disclosure website in order to make  
10 prescription drug price information available to New Jersey  
11 practitioners. The website shall have a dedicated link that is  
12 prominently displayed on the board's home page.

13 b. The website shall include, at a minimum, the following data  
14 elements, separated by therapeutic category:

15 (1) name of the product;

16 (2) whether the drug is brand name or generic;

17 (3) drug strength;

18 (4) per-unit wholesale acquisition cost of the drug, provided to  
19 the board by pharmaceutical manufacturing companies pursuant to  
20 section 2 of P.L. , c. (C. ) (pending before the Legislature as  
21 this bill); and

22 (5) any disclaimers deemed appropriate by the board.

23 c. The board shall actively seek grant funds to implement the  
24 provisions of this section, and implementation shall be contingent  
25 upon the board obtaining sufficient grant funds for the development,  
26 operation, and continued maintenance of the prescription drug pricing  
27 disclosure website. The board shall have the authority to enter into a  
28 contract for the administration of the board's responsibilities pursuant  
29 to this section.

30 d. Each State board and other entity that, under Title 45 of the  
31 Revised Statutes, regulates individuals with prescriptive authority in  
32 New Jersey shall advise the licensees of the board or entity at least  
33 once annually of the opportunity to access the prescription drug  
34 pricing disclosure website.

35  
36 2. a. For the purposes of the prescription drug pricing disclosure  
37 website required by the New Jersey State Board of Pharmacy  
38 pursuant to section 1 of P.L. , c. (C. ) (pending before the  
39 Legislature as this bill), each pharmaceutical manufacturing company  
40 that engages in prescription drug marketing, either directly or through  
41 the use of a pharmaceutical marketer, with a New Jersey practitioner  
42 as defined in section 2 of P.L.2003, c.280 (C.45:14-41), a  
43 practitioner's designee, or any member of a practitioner's staff, shall  
44 provide to the New Jersey State Board of Pharmacy, no later than  
45 January first, April first, July first, and October first of each calendar  
46 year, the current wholesale acquisition cost information for the  
47 pharmaceutical drugs or biological products marketed in the State by  
48 that company.

1       b. The provisions of this section shall only apply to prescription  
2 drug marketing engaged in by a pharmaceutical manufacturing  
3 company and a practitioner, a practitioner's designee, or any member  
4 of a practitioner's staff, while physically present in the state of New  
5 Jersey.

6       c. Any pharmaceutical manufacturing company that fails to  
7 comply with the requirements of this section shall be liable to a  
8 penalty as follows: for the first offense, not less than \$200 nor  
9 more than \$5,000; and, for the second and each succeeding offense,  
10 not less than \$1,000 nor more than \$20,000. The penalties shall be  
11 enforced by the Director of Consumer Affairs in the Department of  
12 Law and Public Safety in a summary proceeding in accordance with  
13 the "Penalty Enforcement Law of 1999," P.L.1999, c.274 (C.2A:58-  
14 10 et seq.).

15       d. For purposes of this section:

16       "Pharmaceutical marketer" means a person who, while employed  
17 by or under contract to represent a pharmaceutical manufacturing  
18 company, engages in prescription drug marketing activities.

19       "Prescription drug marketing" means any activity, including, but  
20 not limited to, in-person meetings, physical mailings, telephonic  
21 conversations, video conferencing, electronic mail, or facsimile, that  
22 provides educational or marketing information or materials regarding a  
23 prescription drug.

24       "Wholesale acquisition cost" means the pharmaceutical  
25 manufacturing company's list price for the pharmaceutical drug or  
26 biological product to wholesalers or direct purchasers in the United  
27 States for the most recent month for which the information is  
28 available, as reported in wholesale price guides or other publications  
29 of pharmaceutical drug or biological product pricing data, not  
30 including prompt pay or other discounts, rebates, or reductions in  
31 price.

32

33       3. This act shall take effect immediately.

34

35

36

STATEMENT

37

38       This bill requires the New Jersey State Board of Pharmacy to  
39 establish a prescription drug pricing disclosure website. In order to  
40 make this information available for the website, the bill further  
41 requires certain pharmaceutical manufacturing companies to provide  
42 prescription drug price information to the board.

43       Under the bill, the board is required to develop a prescription  
44 drug pricing disclosure website in order to make prescription drug  
45 price information available to New Jersey practitioners, who are  
46 individuals currently licensed, registered, or otherwise authorized in  
47 the State to administer or prescribe drugs in the course of  
48 professional practice. The website must have a dedicated link that



**S2389 SINGLETON**

1 is prominently displayed on the board's home page and include, at a  
2 minimum, the following data elements, separated by therapeutic  
3 category: (1) name of the product; (2) whether the drug is brand  
4 name or generic; (3) drug strength; (4) per-unit wholesale  
5 acquisition cost of the drug, provided to the board by pharmaceutical  
6 manufacturing companies as required by the bill; and (5) any  
7 disclaimers deemed appropriate by the board. Each State board and  
8 other entity that, under Title 45 of the Revised Statutes, regulates  
9 individuals with prescriptive authority in New Jersey is required to  
10 advise the licensees of the board or entity at least once annually of the  
11 opportunity to access the prescription drug pricing disclosure website.

12 The bill also requires that each pharmaceutical manufacturing  
13 company that engages in any form of prescription drug marketing,  
14 either directly or through the use of a pharmaceutical marketer, with a  
15 New Jersey practitioner, a practitioner's designee, or any member of a  
16 practitioner's staff, to provide to the board, no later than January first,  
17 April first, July first, and October first of each calendar year, the  
18 current wholesale acquisition cost information for the pharmaceutical  
19 drugs or biological products marketed in the State by that company.  
20 Any pharmaceutical manufacturing company that fails to comply  
21 with these requirements will be liable to a penalty as follows: for  
22 the first offense, not less than \$200 nor more than \$5,000; and, for  
23 the second and each succeeding offense, not less than \$1,000 nor  
24 more than \$20,000.

25 Under the bill, "wholesale acquisition cost" means the  
26 pharmaceutical manufacturing company's list price for the  
27 pharmaceutical drug or biological product to wholesalers or direct  
28 purchasers in the United States for the most recent month for which  
29 the information is available, as reported in wholesale price guides or  
30 other publications of pharmaceutical drug or biological product pricing  
31 data, not including prompt pay or other discounts, rebates, or  
32 reductions in price.

SENATE HEALTH, HUMAN SERVICES AND SENIOR  
CITIZENS COMMITTEE

STATEMENT TO  
**SENATE, No. 2389**

with committee amendments

**STATE OF NEW JERSEY**

DATED: JUNE 3, 2019

The Senate Health, Human Services and Senior Citizens Committee reports favorably and with committee amendments Senate Bill No. 2389.

As amended by the committee, this bill requires the New Jersey State Board of Pharmacy to establish a prescription drug pricing disclosure website. In order to make this information available for the website, the amended bill further requires certain pharmaceutical manufacturing companies to provide prescription drug price information to the board.

Under the bill as amended, the board is required to develop a prescription drug pricing disclosure website in order to make prescription drug price information available to New Jersey practitioners, who are individuals currently licensed, registered, or otherwise authorized in the State to administer or prescribe drugs in the course of professional practice. The website must have a dedicated link that is prominently displayed on the board's home page and include, at a minimum, the following data elements, separated by therapeutic category: (1) name of the product; (2) whether the drug is brand name or generic; (3) drug strength; (4) per-unit wholesale acquisition cost of the drug, provided to the board by pharmaceutical manufacturing companies as required by the bill; and (5) any disclaimers deemed appropriate by the board that are not inconsistent with State and federal law or regulations. Each State board and other entity that, under Title 45 of the Revised Statutes, regulates individuals with prescriptive authority in New Jersey is required to advise the licensees of the board or entity at least once annually of the opportunity to access the prescription drug pricing disclosure website.

The amended bill also requires that each pharmaceutical manufacturing company that engages in any form of prescription drug marketing, either directly or through the use of a pharmaceutical marketer, with a New Jersey practitioner, a practitioner's designee, or any member of a practitioner's staff, to provide to the board, no later than 30 days after the end of each quarter of the calendar year, the current wholesale acquisition cost information for the pharmaceutical

drugs or biological products marketed in the State by that company. Any pharmaceutical manufacturing company that fails to comply with these requirements will be liable to a penalty as follows: for the first offense, not less than \$200 nor more than \$5,000; and, for the second and each succeeding offense, not less than \$1,000 nor more than \$20,000.

Under the bill, "wholesale acquisition cost" means the pharmaceutical manufacturing company's list price for the pharmaceutical drug or biological product to wholesalers or direct purchasers in the United States for the most recent month for which the information is available, as reported in wholesale price guides or other publications of pharmaceutical drug or biological product pricing data, not including prompt pay or other discounts, rebates, or reductions in price.

COMMITTEE AMENDMENTS:

The committee amendments clarify that any additional disclaimers included by the State Board of Pharmacy on the prescription drug pricing website established under the bill are not to be inconsistent with State or federal law or regulations.

The committee amendments revise the reporting requirement for pharmaceutical manufacturers to provide that the required information is to be provided to the State Board of Pharmacy no later than 30 days after the end of each quarter of the calendar year, rather than by January 1, April 1, July 1, and October 1 of each calendar year.

# ASSEMBLY HEALTH AND SENIOR SERVICES COMMITTEE

## STATEMENT TO

[First Reprint]

**SENATE, No. 2389**

# **STATE OF NEW JERSEY**

DATED: DECEMBER 5, 2019

The Assembly Health and Senior Services Committee reports favorably Senate Bill No. 2389 (1R).

This bill requires the New Jersey State Board of Pharmacy to establish a prescription drug pricing disclosure website. In order to make this information available for the website, the bill further requires certain pharmaceutical manufacturing companies to provide prescription drug price information to the board.

Under the bill, the board is required to develop a prescription drug pricing disclosure website in order to make prescription drug price information available to New Jersey practitioners, who are individuals currently licensed, registered, or otherwise authorized in the State to administer or prescribe drugs in the course of professional practice. The website must have a dedicated link that is prominently displayed on the board's home page and include, at a minimum, the following data elements, separated by therapeutic category: (1) name of the product; (2) whether the drug is brand name or generic; (3) drug strength; (4) per-unit wholesale acquisition cost of the drug, provided to the board by pharmaceutical manufacturing companies as required by the bill; and (5) any disclaimers deemed appropriate by the board that are not inconsistent with State and federal law or regulations. Each State board and other entity that, under Title 45 of the Revised Statutes, regulates individuals with prescriptive authority in New Jersey is required to advise the licensees of the board or entity at least once annually of the opportunity to access the prescription drug pricing disclosure website.

The bill also requires that each pharmaceutical manufacturing company that engages in any form of prescription drug marketing, either directly or through the use of a pharmaceutical marketer, with a New Jersey practitioner, a practitioner's designee, or any member of a practitioner's staff, to provide to the board, no later than 30 days after the end of each quarter of the calendar year, the current wholesale acquisition cost information for the pharmaceutical drugs or biological products marketed in the State by that company. Any pharmaceutical manufacturing company that fails to comply with these requirements will be liable to a penalty as follows: for the first offense, not less than

\$200 nor more than \$5,000; and, for the second and each succeeding offense, not less than \$1,000 nor more than \$20,000.

Under the bill, "wholesale acquisition cost" means the pharmaceutical manufacturing company's list price for the pharmaceutical drug or biological product to wholesalers or direct purchasers in the United States for the most recent month for which the information is available, as reported in wholesale price guides or other publications of pharmaceutical drug or biological product pricing data, not including prompt pay or other discounts, rebates, or reductions in price.

As reported by the committee, this bill is identical to Assembly Bill No. 5449 (1R), which was amended, and also reported, by the committee on this date.

# ASSEMBLY, No. 5449

## STATE OF NEW JERSEY 218th LEGISLATURE

INTRODUCED MAY 23, 2019

**Sponsored by:**

**Assemblywoman ANNETTE QUIJANO**

**District 20 (Union)**

**SYNOPSIS**

Requires New Jersey State Board of Pharmacy to establish prescription drug pricing disclosure website and certain pharmaceutical manufacturing companies to provide prescription drug price information.

**CURRENT VERSION OF TEXT**

As introduced.



1 AN ACT concerning the disclosure of prescription drug price  
2 information and supplementing P.L.2003, c.280 (C.45:14-  
3 40 et seq.) and Title 24 of the Revised Statutes.

4  
5 **BE IT ENACTED** by the Senate and General Assembly of the State  
6 of New Jersey:

7  
8 1. a. The New Jersey State Board of Pharmacy shall develop a  
9 prescription drug pricing disclosure website in order to make  
10 prescription drug price information available to New Jersey  
11 practitioners. The website shall have a dedicated link that is  
12 prominently displayed on the board's home page.

13 b. The website shall include, at a minimum, the following data  
14 elements, separated by therapeutic category:

15 (1) name of the product;

16 (2) whether the drug is brand name or generic;

17 (3) drug strength;

18 (4) per-unit wholesale acquisition cost of the drug, provided to  
19 the board by pharmaceutical manufacturing companies pursuant to  
20 section 2 of P.L. , c. (C. ) (pending before the Legislature as  
21 this bill); and

22 (5) any disclaimers deemed appropriate by the board.

23 c. The board shall actively seek grant funds to implement the  
24 provisions of this section, and implementation shall be contingent  
25 upon the board obtaining sufficient grant funds for the development,  
26 operation, and continued maintenance of the prescription drug pricing  
27 disclosure website. The board shall have the authority to enter into a  
28 contract for the administration of the board's responsibilities pursuant  
29 to this section.

30 d. Each State board and other entity that, under Title 45 of the  
31 Revised Statutes, regulates individuals with prescriptive authority in  
32 New Jersey shall advise the licensees of the board or entity at least  
33 once annually of the opportunity to access the prescription drug  
34 pricing disclosure website.

35  
36 2. a. For the purposes of the prescription drug pricing disclosure  
37 website required by the New Jersey State Board of Pharmacy  
38 pursuant to section 1 of P.L. , c. (C. ) (pending before the  
39 Legislature as this bill), each pharmaceutical manufacturing company  
40 that engages in prescription drug marketing, either directly or through  
41 the use of a pharmaceutical marketer, with a New Jersey practitioner  
42 as defined in section 2 of P.L.2003, c.280 (C.45:14-41), a  
43 practitioner's designee, or any member of a practitioner's staff, shall  
44 provide to the New Jersey State Board of Pharmacy, no later than  
45 January first, April first, July first, and October first of each calendar  
46 year, the current wholesale acquisition cost information for the  
47 pharmaceutical drugs or biological products marketed in the State by  
48 that company.

1       b. The provisions of this section shall only apply to prescription  
2 drug marketing engaged in by a pharmaceutical manufacturing  
3 company and a practitioner, a practitioner's designee, or any member  
4 of a practitioner's staff, while physically present in the state of New  
5 Jersey.

6       c. Any pharmaceutical manufacturing company that fails to  
7 comply with the requirements of this section shall be liable to a  
8 penalty as follows: for the first offense, not less than \$200 nor  
9 more than \$5,000; and, for the second and each succeeding offense,  
10 not less than \$1,000 nor more than \$20,000. The penalties shall be  
11 enforced by the Director of Consumer Affairs in the Department of  
12 Law and Public Safety in a summary proceeding in accordance with  
13 the "Penalty Enforcement Law of 1999," P.L.1999, c.274 (C.2A:58-  
14 10 et seq.).

15       d. For purposes of this section:

16       "Pharmaceutical marketer" means a person who, while employed  
17 by or under contract to represent a pharmaceutical manufacturing  
18 company, engages in prescription drug marketing activities.

19       "Prescription drug marketing" means any activity, including, but  
20 not limited to, in-person meetings, physical mailings, telephonic  
21 conversations, video conferencing, electronic mail, or facsimile, that  
22 provides educational or marketing information or materials regarding a  
23 prescription drug.

24       "Wholesale acquisition cost" means the pharmaceutical  
25 manufacturing company's list price for the pharmaceutical drug or  
26 biological product to wholesalers or direct purchasers in the United  
27 States for the most recent month for which the information is  
28 available, as reported in wholesale price guides or other publications  
29 of pharmaceutical drug or biological product pricing data, not  
30 including prompt pay or other discounts, rebates, or reductions in  
31 price.

32

33       3. This act shall take effect immediately.

34

35

36

#### STATEMENT

37

38       This bill requires the New Jersey State Board of Pharmacy to  
39 establish a prescription drug pricing disclosure website. In order to  
40 make this information available for the website, the bill further  
41 requires certain pharmaceutical manufacturing companies to provide  
42 prescription drug price information to the board.

43       Under the bill, the board is required to develop a prescription  
44 drug pricing disclosure website in order to make prescription drug  
45 price information available to New Jersey practitioners, who are  
46 individuals currently licensed, registered, or otherwise authorized in  
47 the State to administer or prescribe drugs in the course of  
48 professional practice. The website must have a dedicated link that



1 is prominently displayed on the board's home page and include, at a  
2 minimum, the following data elements, separated by therapeutic  
3 category: (1) name of the product; (2) whether the drug is brand  
4 name or generic; (3) drug strength; (4) per-unit wholesale  
5 acquisition cost of the drug, provided to the board by pharmaceutical  
6 manufacturing companies as required by the bill; and (5) any  
7 disclaimers deemed appropriate by the board. Each State board and  
8 other entity that, under Title 45 of the Revised Statutes, regulates  
9 individuals with prescriptive authority in New Jersey is required to  
10 advise the licensees of the board or entity at least once annually of the  
11 opportunity to access the prescription drug pricing disclosure website.

12 The bill also requires that each pharmaceutical manufacturing  
13 company that engages in any form of prescription drug marketing,  
14 either directly or through the use of a pharmaceutical marketer, with a  
15 New Jersey practitioner, a practitioner's designee, or any member of a  
16 practitioner's staff, to provide to the board, no later than January first,  
17 April first, July first, and October first of each calendar year, the  
18 current wholesale acquisition cost information for the pharmaceutical  
19 drugs or biological products marketed in the State by that company.  
20 Any pharmaceutical manufacturing company that fails to comply  
21 with these requirements will be liable to a penalty as follows: for  
22 the first offense, not less than \$200 nor more than \$5,000; and, for  
23 the second and each succeeding offense, not less than \$1,000 nor  
24 more than \$20,000.

25 Under the bill, "wholesale acquisition cost" means the  
26 pharmaceutical manufacturing company's list price for the  
27 pharmaceutical drug or biological product to wholesalers or direct  
28 purchasers in the United States for the most recent month for which  
29 the information is available, as reported in wholesale price guides or  
30 other publications of pharmaceutical drug or biological product pricing  
31 data, not including prompt pay or other discounts, rebates, or  
32 reductions in price.

# ASSEMBLY HEALTH AND SENIOR SERVICES COMMITTEE

## STATEMENT TO

### **ASSEMBLY, No. 5449**

with committee amendments

# **STATE OF NEW JERSEY**

DATED: DECEMBER 5, 2019

The Assembly Human Services Committee reports favorably and with committee amendments Assembly Bill No. 5449.

As amended by the committee, this bill requires the New Jersey State Board of Pharmacy to establish a prescription drug pricing disclosure website. In order to make this information available for the website, the amended bill further requires certain pharmaceutical manufacturing companies to provide prescription drug price information to the board.

Under the bill as amended, the board is required to develop a prescription drug pricing disclosure website in order to make prescription drug price information available to New Jersey practitioners, who are individuals currently licensed, registered, or otherwise authorized in the State to administer or prescribe drugs in the course of professional practice. The website must have a dedicated link that is prominently displayed on the board's home page and include, at a minimum, the following data elements, separated by therapeutic category: (1) name of the product; (2) whether the drug is brand name or generic; (3) drug strength; (4) per-unit wholesale acquisition cost of the drug, provided to the board by pharmaceutical manufacturing companies as required by the bill; and (5) any disclaimers deemed appropriate by the board that are not inconsistent with State and federal law or regulations. Each State board and other entity that, under Title 45 of the Revised Statutes, regulates individuals with prescriptive authority in New Jersey is required to advise the licensees of the board or entity at least once annually of the opportunity to access the prescription drug pricing disclosure website.

The amended bill also requires that each pharmaceutical manufacturing company that engages in any form of prescription drug marketing, either directly or through the use of a pharmaceutical marketer, with a New Jersey practitioner, a practitioner's designee, or any member of a practitioner's staff, to provide to the board, no later than 30 days after the end of each quarter of the calendar year, the current wholesale acquisition cost information for the pharmaceutical drugs or biological products marketed in the State by that company. Any pharmaceutical manufacturing company that fails to comply with these requirements will be liable to a penalty as follows: for the first

offense, not less than \$200 nor more than \$5,000; and, for the second and each succeeding offense, not less than \$1,000 nor more than \$20,000.

Under the bill, "wholesale acquisition cost" means the pharmaceutical manufacturing company's list price for the pharmaceutical drug or biological product to wholesalers or direct purchasers in the United States for the most recent month for which the information is available, as reported in wholesale price guides or other publications of pharmaceutical drug or biological product pricing data, not including prompt pay or other discounts, rebates, or reductions in price.

As amended and reported by the committee, this bill is identical to Senate Bill No. 2389 (1R), which was also reported by the committee on this date.

#### COMMITTEE AMENDMENTS:

The committee amendments clarify that any additional disclaimers included by the State Board of Pharmacy on the prescription drug pricing website established under the bill are not to be inconsistent with State or federal law or regulations.

The committee amendments revise the reporting requirement for pharmaceutical manufacturers to provide that the required information is to be provided to the State Board of Pharmacy no later than 30 days after the end of each quarter of the calendar year, rather than by January 1, April 1, July 1, and October 1 of each calendar year.

**SENATE BILL NO. 2389**  
**(First Reprint)**

To the Senate:

Pursuant to Article V, Section I, Paragraph 14 of the New Jersey Constitution, I am returning Senate Bill No. 2389 (First Reprint) with my recommendations for reconsideration.

This bill requires the New Jersey State Board of Pharmacy (the "board") to establish a prescription drug pricing disclosure website for utilization by New Jersey practitioners who are currently licensed, registered, or otherwise authorized in the State to administer or prescribe drugs in the course of professional practice. To facilitate this information sharing, the bill further requires certain pharmaceutical manufacturing companies to provide prescription drug price information to the board.

I share the sponsors' desire to increase the transparency of prescription drug pricing. However, the website contemplated in this bill is more appropriately developed and maintained by the Division of Consumer Affairs (the "Division"). Since 2006, the Division has been responsible for providing consumers retail price information for the most frequently prescribed medications in the State through the New Jersey Prescription Drug Retail Price Registry, N.J.S. 45:14-81 et seq. Because the requirements of this bill dovetail with the Division's current disclosure responsibilities related to prescription drug costs, I am recommending revisions to require the Division, rather than the board, to establish and maintain the prescription drug pricing disclosure website.

Additionally, I believe the bill could be improved by setting forth a clear time frame in which to establish the disclosure website. Specifically, my recommended revisions require the Division to establish the disclosure website no later than six months after the Division has received grant funds in an amount sufficient to develop and maintain the website.

Accordingly, I herewith return Senate Bill No. 2389

(First Reprint) and recommend that it be amended as follows:

- Page 2, Title, Lines 2-3: Delete "P.L.2003, c.280 (C.45:14-40 et seq.)" and insert "P.L.2006, c.84 (C.45:14-81 et seq.)"
- Page 2, Section 1, Line 8: Delete "The New Jersey State Board of Pharmacy" and insert "As provided in subsection c. of this section, the Division of Consumer Affairs in the Department of Law and Public Safety"
- Page 2, Section 1, Line 12: Delete "board's" and insert "division's"
- Page 2, Section 1, Line 19: Delete "board" and insert "division"
- Page 2, Section 1, Line 22: Delete "board" and insert "New Jersey State Board of Pharmacy"
- Page 2, Section 1, Line 24: Delete "board" and insert "division"
- Page 2, Section 1, Line 26: Delete "board" and insert "division"
- Page 2, Section 1, Line 28: Delete "board" and insert "division"
- Page 2, Section 1, Line 30: Delete "board's" and insert "division's"
- Page 2, Section 1, Line 30: After "section." insert "The division shall establish the disclosure website no later than six months after it receives grant funds in an amount sufficient to develop and operate the website as provided in this subsection."
- Page 2, Section 2, Lines 38-39: Delete "by the New Jersey State of Board of Pharmacy"
- Page 2, Section 2, Line 45: Delete "New Jersey"
- Page 3, Section 2, Line 1: Delete "State Board of Pharmacy" and insert "Division of Consumer Affairs in the Department of Law and Public Safety"

Respectfully,

[seal]

/s/ Philip D. Murphy

Governor

Attest:

/s/ Matthew J. Platkin

Chief Counsel to the Governor

January 9, 2020

**SENATE BILL NO. 2389**  
**(First Reprint)**

To the Senate:

Pursuant to Article V, Section I, Paragraph 14 of the New Jersey Constitution, I am returning Senate Bill No. 2389 (First Reprint) with my recommendations for reconsideration.

This bill requires the New Jersey State Board of Pharmacy (the "board") to establish a prescription drug pricing disclosure website for utilization by New Jersey practitioners who are currently licensed, registered, or otherwise authorized in the State to administer or prescribe drugs in the course of professional practice. To facilitate this information sharing, the bill further requires certain pharmaceutical manufacturing companies to provide prescription drug price information to the board.

I share the sponsors' desire to increase the transparency of prescription drug pricing. However, the website contemplated in this bill is more appropriately developed and maintained by the Division of Consumer Affairs (the "Division"). Since 2006, the Division has been responsible for providing consumers retail price information for the most frequently prescribed medications in the State through the New Jersey Prescription Drug Retail Price Registry, N.J.S. 45:14-81 et seq. Because the requirements of this bill dovetail with the Division's current disclosure responsibilities related to prescription drug costs, I am recommending revisions to require the Division, rather than the board, to establish and maintain the prescription drug pricing disclosure website.

Additionally, I believe the bill could be improved by setting forth a clear time frame in which to establish the disclosure website. Specifically, my recommended revisions require the Division to establish the disclosure website no later than six months after the Division has received grant funds in an amount sufficient to develop and maintain the website.

Accordingly, I herewith return Senate Bill No. 2389 (First Reprint) and recommend that it be amended as follows:

- Page 2, Title, Lines 2-3: Delete "P.L.2003, c.280 (C.45:14-40 et seq.)" and insert "P.L.2006, c.84 (C.45:14-81 et seq.)"
- Page 2, Section 1, Line 8: Delete "The New Jersey State Board of Pharmacy" and insert "As provided in subsection c. of this section, the Division of Consumer Affairs in the Department of Law and Public Safety"
- Page 2, Section 1, Line 12: Delete "board's" and insert "division's"
- Page 2, Section 1, Line 19: Delete "board" and insert "division"
- Page 2, Section 1, Line 22: Delete "board" and insert "New Jersey State Board of Pharmacy"
- Page 2, Section 1, Line 24: Delete "board" and insert "division"
- Page 2, Section 1, Line 26: Delete "board" and insert "division"
- Page 2, Section 1, Line 28: Delete "board" and insert "division"
- Page 2, Section 1, Line 30: Delete "board's" and insert "division's"
- Page 2, Section 1, Line 30: After "section." insert "The division shall establish the disclosure website no later than six months after it receives grant funds in an amount sufficient to develop and operate the website as provided in this subsection."
- Page 2, Section 2, Lines 38-39: Delete "by the New Jersey State of Board of Pharmacy"
- Page 2, Section 2, Line 45: Delete "New Jersey"
- Page 3, Section 2, Line 1: Delete "State Board of Pharmacy" and insert "Division of Consumer Affairs in the Department of Law and Public Safety"

Respectfully,

[seal]

/s/ Philip D. Murphy

Governor

Attest:

/s/ Matthew J. Platkin

Chief Counsel to the Governor

# Governor Murphy Takes Action on Legislation

01/21/2020

**TRENTON** – Today, Governor Phil Murphy signed the following bills into law:

**S-62/A-2478 (Singleton, Oroho/DeAngelo, Houghtaling, Space)** – Requires certain contractors to register under "The Public Works Contractor Registration Act"

**S-358/A-4587 (Rice/Sumter, Reynolds-Jackson)** – Establishes database with certain information about individuals elected to public office in this State

**S-376/A-3839 (Madden, Gopal/Moriarty, Lagana, Mukherji, Murphy)** – Eliminates eligibility time limit on tuition benefits for spouses of certain public safety workers killed in performance of their duties

**S-497/A-4626 (Vitale, Madden/Mosquera, McKnight, Vainieri Huttle)** – Allows certain prior statements by children to be admitted into evidence in child abuse and termination of parental rights cases

**S-498/ACS for A-3391 (Vitale, Oroho/DeCroce, Johnson, DiMaso)** – Makes various changes to "Criminal Injuries Compensation Act of 1971"

**S-521/A-4378 (T. Kean, C.A. Brown, Pou, Ruiz/Caputo, Mukherji, Vainieri Huttle)** – Requires NJ State Council on Arts to establish "Artist District" designation and select certain municipalities or areas within municipalities for such designation

**S-589/ACS for A-422 (Weinberg/Mosquera, Jones, Moriarty)** – Requires Secretary of State to establish secure Internet website for online voter registration; authorizes use of digitized signatures from New Jersey Motor Vehicle Commission's database

**S-700/A-3836 (Ruiz, Cunningham/Schaer, Mukherji, Jasey)** – "Higher Education Citizenship Equality Act"; defines domicile for dependent students for purpose of eligibility for State student grants and scholarships, and resident tuition rate

**S-721/A-1751 (Greenstein, Cunningham, Diegnan/Quijano, Benson)** – Authorizes use of certain electric school buses

**S-758/A-1987 (Cunningham, Cruz-Perez/Sumter, Mukherji, Quijano)** – Requires incarcerated individual from State to be counted at residential address for legislative redistricting purposes

**S-765/A-541 (Cunningham, T. Kean, Ruiz/Mazzeo, Jasey, Vainieri Huttle, Sumter, Benson)** – Prohibits Higher Education Student Assistance Authority from referring defaulted loans under New Jersey College Loans to Assist State Students (NJCLASS) Loan Program for certain actions if authority and borrower have entered into settlement agreement

**S-782/A-1110 (Sarlo, Scutari/Downey, Houghtaling, Dancer)** – Increases workers' compensation for loss of hand or foot

**S-834 wGR/A-4186 (Scutari, Greenstein/Jones, Pintor Marin)** – Prohibits resale of non-prescription diabetes test devices by pharmacists

**S-939/A-3331 (Pou/Vainieri Huttle, Lopez, McKnight)** – Requires forms and materials for individuals with developmental disabilities to be available in languages other than English

**S-974/A-3040 (Singleton, T. Kean/Vainieri Huttle, Timberlake, Mosquera)** – Requires newborn infants be screened for spinal muscular atrophy



- S-1032/A-2389 (Vitale, Gopal/Schaer, Benson, Verrelli)** – Concerns expansion of services provided by DHS mental health screening services
- S-1146/A-2365 (Codey, Rice/Vainieri Huttle, Mukherji, Downey)** – Requires hospital patient's medical record to include notation if patient is at increased risk of confusion, agitation, behavioral problems, and wandering due to dementia related disorder
- S-1298/ACS for A-2972 (A.M. Bucco, Singleton/Mazzeo, Dunn, Space)** – Permits municipalities to provide information on property tax bills concerning amount of local tax dollars saved through shared services
- S-1318/A-3156 (Ruiz, Scutari/Lampitt, Mosquera)** – Permits counties and non-governmental, community-based agencies to establish family justice centers which provide coordinated, multi-agency governmental and non-governmental assistance to victims of certain crimes and offenses, including domestic violence, and their family members
- S-1505/A-1707 (Vitale/Vainieri Huttle, Lampitt, Benson, Mosquera)** – Expands membership of NJ Task Force on Child Abuse and Neglect
- S-1647/A-3181 (Diegnan, Codey/Conaway, Vainieri Huttle, Benson, Murphy)** – Prohibits use of coupons, price rebates, and price reduction promotions in sales of tobacco and vapor products
- S-1683/A-4267 (Smith, Greenstein/McKeon, Space, Wirths)** – Concerns regulation of solid waste, hazardous waste, and soil and fill recycling industries
- S-1703/A-715 (Connors, Holzapfel/Gove, Rumpf, DiMaso)** – Exempts disabled veterans from beach buggy permit fees
- S-1791/A-3414 (Weinberg/Johnson, Vainieri Huttle, Houghtaling)** – Requires employers to disclose certain wage information to employees
- S-1796/A-4693 (Addiego, Sweeney/Murphy)** – Permits school district of residence to provide aid in-lieu-of transportation to pupil attending Marine Academy of Science and Technology provided certain conditions are met
- S-1832/A-211 (Ruiz, Sarlo/Chiaravalloti, Zwicker, Pintor Marin)** – Establishes loan redemption program and tuition reimbursement program for certain teachers of science, technology, engineering, and mathematics
- S-2267/A-3616 (Sweeney, Corrado/Burzichelli, Holley, Calabrese)** – Gives State lottery winners option of remaining anonymous indefinitely
- S-2303/A-4843 (Sweeney, Ruiz, Cunningham/Wimberly, Karabinchak, Calabrese)** – Requires establishment of Work and Learn Consortiums by certain educational institutions to establish certificate and degree programs identified in high labor-demand industries
- S-2389 wGR/A-5449 (Singleton/Quijano, Downey, Houghtaling, Moriarty)** – Requires New Jersey State Board of Pharmacy to establish prescription drug pricing disclosure website and certain pharmaceutical manufacturing companies to provide prescription drug price information
- S-2428/A-4965 (Scutari/Quijano, Vainieri Huttle)** – Requires that massage and bodywork therapists and employers carry professional liability insurance
- S-2469/A-3745 (Singleton, Oroho/Wirths, Mazzeo, Space)** – Prohibits person from contracting for public work if person is federally debarred from receiving federal contract
- S-2511/A-4020 (Madden/Mazzeo, Murphy, Johnson)** – Changes title of DEP "conservation officer" to "conservation police officer"
- S-2521/A-4087 (Cryan, Greenstein/Vainieri Huttle, Lopez, Timberlake)** – Requires reporting of inmate abuse by employees of State correctional facilities and establishes reporting and investigation program
- S-2522/A-4090 (Cryan, Greenstein/Vainieri Huttle, Lopez, Timberlake)** – Limits cross gender strip searches in

## State correctional facilities

**S-2532/A-4086 (Greenstein, Cruz-Perez/Vainieri Huttle, Lopez, Timberlake)** – Requires correctional police officers receive 20 hours in-service training, including four hours in prevention of sexual misconduct, non-fraternization, and manipulation

**S-2555/A-3990 (Gopal, Ruiz/Mukherji, Benson, Karabinchak)** – Allows dependent students whose parents or guardians hold H-1B visas to qualify for in-State tuition at public institutions of higher education provided they meet certain criteria

**S-2564/A-3519 (Turner, Singleton/Benson, McKnight, Jasey)** – Establishes "Restorative Justice in Education Pilot Program" in Department of Education

**SCS for S-2599/ACS for A-1268 (Bateman, Beach/Tucker, Conaway, Lampitt, Quijano)** – Authorizes veterans' property tax exemption and veterans' property tax deduction for honorably discharged veterans of United States Armed Forces who did not serve in time of war or other emergency

**S-2826/A-3274 (Greenstein/Vainieri Huttle, Dancer, Benson)** – Requires institutions of higher education to offer cats and dogs no longer used for educational, research, or scientific purposes for adoption; designated the "Homes for Animal Heroes Act"

**S-2849/A-4590 (A.M. Bucco/DiMaio, Caputo, Dunn)** – Designates Seeing Eye® dog as State Dog

**S-3036/A-1697 (Lagana, Scutari/Dancer, Downey)** – Prohibits medical providers from reporting certain workers' compensation medical charges to collection and credit reporting agencies

**S-3061/A-4603 (Ruiz, Greenstein/Lampitt, Mukherji, Benson)** – Provides corporation business tax and gross income tax credits for businesses that participate in DOL registered apprenticeship programs; establishes grant program for tax-exempt organizations participating in DOL registered apprenticeship programs

**S-3065/A-4657 (Ruiz, Singleton/Armato, Benson, Timberlake)** – Establishes youth apprenticeship pilot program in Department of Education

**S-3067/A-4602 (Ruiz, Singleton/Lampitt, Reynolds-Jackson, Sumter)** – Establishes five year Apprentice Assistance and Support Services Pilot Program

**S-3116/A-4683 (Ruiz/Speight, Munoz, Tucker)** – Requires certain medical facilities to undertake end-of-life planning and training

**S-3117/A-4685 (Ruiz/Speight, Pinkin, Munoz)** – Requires emergency departments to take certain measures concerning palliative care for patients

**S-3126/A-4107 (Gopal/Benson, DeCroce, Chiaravalloti)** – Requires drivers to stop at railroad crossing when on-track equipment is approaching railroad crossing

**S-3170/A-5145 (Cryan, Pou/Quijano, Milam, Land)** – Increases prenotification time and requires severance pay in certain plant closings, transfers, and mass layoffs

**S-3227/A-5261 (Gopal/Tully, Pinkin, Swain)** – Requires restaurants to post signs advising customers to notify servers of food allergies; requires restaurant managers to complete food allergen training

**S-3265/A-3178 (Turner, Codey, Vitale/Conaway, Murphy, Vainieri Huttle)** – Prohibits sale or distribution of flavored vapor products

[Copy of Statement](#)

**S-3330 wGR/A-5066 (Addiego, Singleton/Jones, Vainieri Huttle, Lampitt, Murphy)** – Establishes pilot program in DCF to study impact of child care services provided by community providers operating in public school facilities; requires community providers to meet certain criteria

**S-3422/A-6056 (Singer, T. Kean/Houghtaling, Downey, Vainieri Huttle)** – Requires declaration of Code Blue

alert when National Weather Service predicts temperatures of 32 degrees Fahrenheit or lower

**S-3468/A-5105 (Sweeney, Singleton/Murphy, Karabinchak, Vainieri Huttle)** – Establishes Task Force on Maximizing Employment for People with Disabilities

**S-3511/A-5298 (Singer, T. Kean/Mukherji, Vainieri Huttle, Downey)** – Authorizes certain health care and social service resources to be made available during Code Blue alert

**S-3581/A-5963 (Singleton/Lopez, Quijano)** – Prohibits certain business financing contracts that contain judgment by confession provisions

**S-3685/A-5345 (Sarlo, Singleton/Mukherji, Conaway, McKnight)** – Establishes program to increase participation of underrepresented students in New Jersey's science and engineering workforce

**S-3756/A-6115 (Ruiz, Sarlo, O'Scanlon/Jasey, Jones, Wirths)** – Requires limited purpose regional school districts to coordinate with constituent districts regarding school calendar and curriculum

**S-3763/A-6116 (Addiego, Bateman, Sarlo/DeAngelo, Dancer, Space)** – Renames joint meetings as regional service agencies; grandfathers existing joint meetings

**S-3869/A-5561 (Sarlo/Burzichelli, Houghtaling)** – Prohibits local governments from imposing fines on alarm companies in certain circumstances

**S-3871/A-5427 (Bateman, Scutari/DePhillips, McKeon)** – Adds member from Retired Judges Association of New Jersey to State Investment Council

**SCS for S-3878/ACS for A-5394 (Ruiz, Weinberg, Cunningham/Moriarty, McKnight, Pinkin)** – Reaffirms and clarifies that Attorney General and Division on Civil Rights may initiate actions in Superior Court to enforce "Law Against Discrimination"

**S-3920 wGR/A-5552 (Pou/Wimberly, Sumter)** – Concerns provision of energy to certain manufacturing facilities by providing exemptions to certain energy related taxes

**S-3923/A-5680 (Madden, Singleton/Giblin, Timberlake, Murphy)** – Concerns labor harmony agreements for hospitality projects

**SCS for S-3939 and 3944/ACS for A-5681 and 5682 (Smith, Greenstein, Bateman, Codey/Pinkin, Lopez, McKeon)** – Establishes Recycling Market Development Council

**S-3985/A-5663 (Smith/McKeon, Pinkin, Vainieri Huttle)** – Amends "Electric Discount and Energy Competition Act" to add definition of "open access offshore wind transmission facility" and revises law concerning "qualified offshore wind projects"

**S-4025/A-5695 (Pou/Wimberly, Sumter)** – Makes FY 2020 language allocation of \$1,000,000 appropriated to Grants for Urban Parks to Hinchliffe Stadium in Paterson

**S-4162/A-6014 (Smith, Greenstein/Vainieri Huttle, Pinkin, Houghtaling)** – Establishes NJ Climate Change Resource Center at Rutgers University; appropriates up to \$500,000

**S-4165/A-4364 (Rice/Giblin, Caputo, Tucker)** – Expands University Hospital board of directors membership from 11 to 13 members

**S-4188/A-6075 (Beach/Murphy, Dancer, Lampitt)** – "Lindsay's Law"; provides tax benefits to organ and bone marrow donors and their employers, and provides paid time off to donors who are State or local government employees

**S-4200/A-5855 (Ruiz, Turner/Coughlin, Lampitt, Holley)** – Requires State to pay difference between federal allocation and total cost of reduced price breakfast or lunch; appropriates \$4.5 million

**S-4247/A-6049 (Gopal, O'Scanlon/Conaway, Houghtaling, Downey)** – Establishes criteria for distribution of Fiscal Year 2020 funding to Community Food Bank of New Jersey and partner organizations

**S-4264/A-5962 (Pou/Wimberly, Sumter, Calabrese)** – Designates State Highway Route 19 as "William J. Pascrell Jr. Highway"

**S-4275/A-6088 (Smith, Greenstein/Burzichelli)** – Allows BPU to increase cost to customers of Class I renewable energy requirement for energy years 2022 through 2024, under certain conditions

**S-4276/A-6109 (Corrado, Bateman/Armato, Calabrese, Land)** – Appropriates \$32,153,936 to State Agriculture Development Committee, and amends 2017 appropriations for stewardship activities, for farmland preservation purposes

**S-4277/A-6112 (Greenstein, Bateman/Freiman, Danielsen, Downey)** – Appropriates \$5,000,000 from constitutionally dedicated CBT revenues to State Agriculture Development Committee for municipal planning incentive grants for farmland preservation purposes

**S-4278/A-6108 (Greenstein, Bateman/Taliaferro, Karabinchak, Kennedy)** – Appropriates \$21 million from constitutionally dedicated CBT revenues to State Agriculture Development Committee for county planning incentive grants for farmland preservation purposes

**S-4279/A-6106 (Smith, Bateman/Houghtaling, Reynolds-Jackson, Pinkin)** – Appropriates \$1,350,000 from constitutionally dedicated CBT revenues to State Agriculture Development Committee for grants to certain nonprofit organizations for farmland preservation purposes

**S-4286/A-5890 (Vitale/Swain, Jones)** – Clarifies procedures concerning collection of child support on behalf of child over age 19 when court has ordered such support

**S-4309/A-6107 (Turner, Cruz-Perez/Mejia, Vainieri Huttie, Zwicker)** – Appropriates \$13,902,723 from constitutionally dedicated CBT revenues to NJ Historic Trust for grants for certain historic preservation projects and associated administrative expenses

**S-4310/A-6114 (Codey, Bateman/Carter, Murphy, Lopez)** – Appropriates \$8,872,682 to DEP from constitutionally dedicated CBT revenues for grants to certain nonprofit entities to acquire or develop lands for recreation and conservation purposes

**S-4311/A-6113 (Greenstein, Bateman/Speight, Mukherji, Verrelli)** – Appropriates \$77,450,448 from constitutionally dedicated CBT revenues and various Green Acres funds to DEP for local government open space acquisition and park development projects

**S-4312/A-6111 (Smith, Bateman/Giblin, Mazzeo, Land)** – Appropriates \$36.143 million from constitutionally dedicated CBT revenues for recreation and conservation purposes to DEP for State capital and park development projects

**S-4313/A-6110 (Corrado, Bateman/Moriarty, McKeon, Swain)** – Appropriates \$33.915 million from constitutionally dedicated CBT revenues to DEP for State acquisition of lands for recreation and conservation purposes, including Blue Acres projects

**SCS for S-4315/ACS for A-6063 (Beach, Turner/Jones, Zwicker)** – Creates fund to reimburse local units of government for cost of certain mail-in ballot procedures; appropriates \$3,000,000

**SJR-51/AJR-189 (Rice, Turner/Verrelli, Reynolds-Jackson, Sumter)** – Establishes the "New Jersey State Commission on Urban Violence"

**SJR-65/AJR-90 (Weinberg, Addiego/DiMaso, Vainieri Huttie, Schepisi)** – Designates March 19th "Women in Public Office Day" in New Jersey

**SJR-80/AJR-121 (Lagana, Weinberg/Jones, Benson, Chiaravalloti, DeCroce)** – Urges federal government to adhere to commitment to improve Northeast Corridor rail infrastructure by providing funding to complete Gateway Program

**SJR-125/AJR-169 (Gopal, Codey/Wolfe, Pinkin)** – Designates the second week of October of each year as "Obesity Care Week" in NJ

- A-344/S-1575 (Murphy, McKeon, Timberlake/Cruz-Perez, Singleton)** – Revises certain aspects of the New Jersey Individual Development Account Program
- A-1040/S-3928 (Houghtaling, Taliaferro/Andrzejczak)** – Establishes NJ "Landowner of the Year" award program
- A-1146/S-4330 (Wimberly, Holley/Pou, Singleton)** – Establishes "New Jersey Investing in You Promise Neighborhood Commission"
- A-1277/S-2629 (Tucker, Holley, Lopez/Singleton, Gopal)** – Requires hospitals and homeless shelters to provide information on services and resources to individuals who are homeless or military veterans
- A-1449/S-3168 (Benson, DeAngelo/Greenstein, Turner)** – Provides job security to certain organ and bone marrow donors
- A-1477/S-3228 (Chaparro, Vainieri Huttle, Benson, Jimenez, Mukherji, Downey/Gopal, Scutari)** – Establishes Statewide Hit and Run Advisory Program to facilitate apprehension of persons fleeing motor vehicle accident scene; designated as "Zackhary's Law"
- A-1478/S-1648 (Chaparro, Vainieri Huttle/Diegnan, T. Kean)** – Revises law governing theater liquor licenses
- A-1604/S-2734 (Conaway, Murphy, Jimenez/Singleton)** – "Recreational Therapists Licensing Act"
- A-1796/S-2609 (McKeon, Downey/Lagana, Gopal)** – Prevents criminal defendant from asserting "gay and transgender panic" defense to murder charge in order to reduce charge to manslaughter committed in heat of passion
- A-1924/S-2930 (Mukherji, A.M. Bucco, DeAngelo, DeCroce/Beach)** – Exempts certain honorably discharged United States military veterans from initial insurance producer licensing fee
- A-1992/S-1780 (Sumter, Benson, Vainieri Huttle, Houghtaling, Wimberly/Diegnan, Turner)** – "New Jersey Call Center Jobs Act"
- A-2183/S-1687 (Land, Johnson/Cruz-Perez, Andrzejczak)** – "Music Therapist Licensing Act"
- ACS for A-2431 wGR/SCS for S-1865 (Benson, Jimenez, DeCroce/Weinberg, T. Kean)** – Requires health insurers to provide plans that limit patient cost-sharing concerning certain prescription drug coverage
- ACS for A-2444 and S-2656/S-2081 (Benson, Lampitt, Pinkin, Mukherji/Turner, Singleton)** – Provides for coverage of comprehensive tobacco cessation benefits in Medicaid
- A-2767/S-2924 (Greenwald, Mosquera, McKnight/Greenstein, Singleton)** – Amends certain provisions of sexual assault statute to clarify elements necessary for conviction
- A-3312/S-1972 (Murphy, Lagana, Downey, Sumter/Gopal, Corrado)** – Requires Legislature to adopt and distribute policy prohibiting sexual harassment; requires members, officers, and employees of Legislature to complete online training on policy once every two years
- A-3670/S-995 (Benson, Giblin, Murphy/Vitale, Weinberg)** – Provides for designation of acute stroke ready hospitals, establishes Stroke Care Advisory Panel and Statewide stroke database, and requires development of emergency medical services stroke care protocols
- ACS for A-4136/SCS for S-2675 (Land, Milam/Andrzejczak, Van Drew)** – Establishes Possession In Excess of Daily Limit Vessel License for black sea bass and summer flounder; dedicates fees therefrom to marine fisheries programs
- A-4147/S-2744 (Lampitt, Houghtaling, Zwicker/Ruiz, Corrado)** – Requires school districts and nonpublic schools to conduct audit of security features of buildings, grounds, and communication systems and to submit audit to NJ Office of Homeland Security and Preparedness and DOE

- A-4150/S-2742 (Lampitt, Jones, Timberlake/Ruiz, Corrado)** – Requires meeting between student and appropriate school personnel after multiple suspensions or proposed expulsion from public school to identify behavior or health difficulties
- A-4151/S-2745 (Swain, Tully, Jasey/Ruiz, Corrado)** – Requires school security training for persons employed by public and nonpublic schools in substitute capacity and for employees and volunteers of youth programs operated in school buildings
- A-4260/S-4335 (Timberlake, Giblin, Tucker, Caputo/Pou, Scutari)** – Prohibits sale of certain toy guns and imitation firearms
- A-4370/S-2919 (Carroll/A.M. Bucco)** – Increases membership of board of trustees of Washington Association of New Jersey
- A-4377/S-2934 (Benson, Land, DeCroce/Greenstein)** – Requires DOT and OIT to develop materials concerning capabilities of airports in NJ and establishes "Public Use Airports Task Force"
- A-4517/S-4341 (Wimberly, Speight, Reynolds-Jackson/Singleton, Cunningham)** – Establishes "New Jersey Eviction Crisis Task Force"
- A-4529/S-3191 (Mazzeo, Armato/Gopal, Andrezejczak)** – Concerns reimbursements to Superstorm Sandy-impacted homeowners subjected to contractor fraud
- A-4563/S-3096 (Zwicker, Benson/Greenstein, Gill)** – Prohibits use of bots to deceive person about origin and content of communication for certain commercial or election purposes
- A-4564/S-3087 (Zwicker, Freiman/Greenstein)** – Establishes "Voting Precinct Transparency Act;" requires filing of election district, county district, and municipal ward boundary data with Secretary of State for posting and download on official website with matching election results data
- A-4699/S-2938 (Moriarty, Burzichelli, Bramnick/Turner)** – Regulates annual report filing services
- A-4803/S-4211 (Greenwald, Johnson, Pintor Marin/Cryan, Vitale)** – Authorizes certain entities to directly bill Victims of Crime Compensation Office for counseling services provided to victims of firearm and stabbing crimes
- A-4822/S-3408 (Wimberly, Tully, Swain/Singleton, Greenstein)** – Permits municipalities to lease vacant municipal land for tiny home occupancy; directs DCA to enhance regulatory guidance on acceptable tiny home construction and use
- A-4904 wGR/S-3347 (Mukherji, Quijano, Mazzeo/Cryan, Sweeney)** – Concerns property taxes due and owing on real property owned by certain federal employees or contractors under certain circumstances
- A-4954/S-3368 (Quijano, Murphy, Carter/Singleton, Greenstein)** – Revises requirements for provision of counseling and support services to emergency services personnel
- ACS for A-4972/SCS for S-1490 (Moriarty/Beach, Scutari)** – Establishes certain consumer protections related to arbitration organizations
- A-4978 wGR/S-3498 (Timberlake, Zwicker, Vainieri Huttle/Greenstein, Cryan)** – Prohibits online education services from using and disclosing certain information, engaging in targeted advertising, and requires deletion of certain information in certain circumstances
- A-5023/S-3467 (McKnight, Mukherji, Chaparro, Chiaravalloti/Cunningham)** – Exempts from DOT permitting requirements certain signs not located in protected areas that have been approved by municipality
- A-5028/S-3523 (Mukherji, Conaway, Pintor Marin/Vitale, Diegnan)** – Establishes "James Nicholas Rentas's Law," revises "New Jersey SmokeFree Air Act"
- A-5029/S-3522 (Sumter, Reynolds-Jackson, Johnson/Rice, T. Kean)** – Requires New Jersey Office on Minority and Multicultural Health to study racial disparities on sexual and reproductive health of African-American women

**A-5031/S-3455 (Speight, McKnight, Timberlake/Ruiz)** – Requires hospital emergency departments to ask person of childbearing age about recent pregnancy history

**A-5314/S-3692 (Zwicker, Milam, Mazzeo/Cryan, Ruiz)** – Requires DHS to study social isolation occurring in certain population groups

**A-5344/S-3833 (Mukherji, Vainieri Huttel, Milam/Gopal, Corrado)** – Establishes uniform standard for acceptable proof of veteran status for veteran's ID cards and various State and local programs

**A-5388/S-3895 (Speight, Pintor Marin, Greenwald/Greenstein, Ruiz)** – Requires specialized in-service training regarding crime victims for police departments in certain high-crime areas

**A-5389/S-3896 (Speight, Pintor Marin, Greenwald/Greenstein, Ruiz)** – Requires training or experience in crime victims' rights for certain members of Victims of Crime Compensation Review Board

**A-5432/S-3796 (Milam, Land/Andrzejczak)** – Requires DEP Commissioner to establish individual transferable quota system for menhaden purse seine fishery

**A-5445/S-3909 (Swain, Tully, Spearman/T. Kean, Corrado)** – Requires AG to establish program to detect fentanyl in State's illegal drug supply and make information related to presence of fentanyl available in database accessible by law enforcement

**A-5511/S-1852 (Spearman, Jones, Reynolds-Jackson/Turner, Cruz-Perez)** – Revises certain penalties for illegal operation of snowmobile, all-terrain vehicle, or dirt bike

**A-5580/S-3842 (Johnson, Moriarty, Greenwald/Weinberg, Sarlo)** – Extends availability period for tax credits for certain expenses incurred for production of certain film and digital media content, raises annual cap related to film production, and provides for annual administration of film tax credits

**A-5583/S-3919 (Pinkin, Lopez, Mukherji/Smith, Bateman)** – Prohibits sale, lease, rent, or installation of certain equipment or products containing hydrofluorocarbons or other greenhouse gases

**A-5630/S-3981 (Pintor Marin, Munoz, Reynolds-Jackson/Weinberg, Corrado)** – Requires Civil Service Commission to establish and maintain hotline for State employees to submit reports of workplace discrimination and harassment

#### [Copy of Statement](#)

**A-5667/S-3933 (Mukherji, Vainieri Huttel, Armato, DeCroce, Karabinchak/Singer, Scutari)** – "Charlie's Law"; requires pharmacy practice sites and hospice programs to furnish patients with information and means to safely dispose of unused prescription drugs and medications

**A-5801/S-4064 (Coughlin, Houghtaling, Verrelli/Singleton, Sweeney)** – Concerns responsibility of contractors for wage claims against subcontractors

**A-5817/S-4263 (Mazzeo, Armato/Cunningham, Sweeney, C.A. Brown)** – Allows certain persons to qualify for casino key employee license and casino employee registration

**A-5916/S-4255 (Chiaravalloti, McKnight, Karabinchak/Cunningham, Weinberg)** – Authorizes DOH to notify elected officials of financial distress of certain hospitals

**A-5918/SCS for S-3741 and 4253 (Chiaravalloti, McKnight/Weinberg, Cunningham, Vitale)** – Expands hospital reporting requirements

**A-5970/S-4201 (Lopez, Speight, Chaparro/Codey)** – Amends list of environmental infrastructure projects approved for long-term funding for FY2020 to include new projects, remove certain projects, and modify estimated loan amounts for certain projects

**A-5971/S-4202 (Mukherji, Pintor Marin, Spearman/Bateman, Corrado)** – Authorizes NJ Infrastructure Bank to expend additional sums to make loans for environmental infrastructure projects for FY2020

**A-5972/S-4203 (Pinkin, Benson, Zwicker/Greenstein, Singleton)** – Makes changes to New Jersey Infrastructure Bank's enabling act

**A-5977/S-4282 (Greenwald, Downey, Vainieri Huttie/Vitale, Singleton)** – Provides for establishment of Regional Health Hub Program as replacement to Accountable Care Organization Demonstration Project, and designates existing accountable care organizations and look-alike organizations as Regional Health Hubs

**A-6119/S-4336 (Egan, Houghtaling/Madden)** – Revises "The Public Works Contractor Registration Act" and amends definition of registered apprenticeship program

**AJR-35/SJR-159 (McKnight, Chaparro, Chiaravalloti, DeCroce/Cunningham, Greenstein)** – Designates third full week in March as "Domestic Violence Services Awareness Week" to bring awareness of services available to domestic violence victims

**AJR-103/SJR-70 (Rooney, DePhillips, Murphy/Corrado)** – Permanently designates January as "NUT Carcinoma Awareness Month" in New Jersey

**AJR-118/SJR-157 (McKnight, Timberlake, McKeon/Pou, Madden)** – Designates April of each year as "Financial Literacy Month" in New Jersey

**AJR-180/SJR-112 (DeAngelo, McKnight, Murphy/Singleton, Corrado)** – Designates February in each year as "Career and Technical Education Month" in New Jersey

**Governor Murphy declined to sign the following bills, meaning they expire without becoming law:**

**S-691/A-657 (Ruiz, Pou/Jasey, Caputo, Pintor Marin, Sumter, Wimberly)** – Requires that if a school district satisfies 80% or more of the required NJ Quality Single Accountability Continuum standards in an area of district effectiveness under State intervention, the State must return that area to local control

**S-1083/A-544 (Cruz-Perez, Gopal/Mazzeo, Houghtaling, Holley, Dancer)** – Establishes loan program and provides corporation business tax and gross income tax credits for establishment of new vineyards and wineries

**S-2421/A-1030 (Smith, Bateman/Johnson, Kennedy, Benson, DeAngelo)** – Concerns installation of electric vehicle charging stations in common interest communities

**S-2425/A-3851 (Singleton, Andrzejczak/Conaway)** – Revises law relating to common interest communities

**S-2429/A-4028 (Scutari, Pou/Bramnick, Downey)** – Requires automobile insurers to disclose policy limits upon request by an attorney under certain circumstances

**S-2835/A-3926 (Singleton, Ruiz/Conaway, Lampitt, Murphy)** – Requires public schools to administer written screenings for depression for students in certain grades

**S-2897/A-1433 (Madden, Singer/Benson, Wimberly, Carter)** – Requires DCA to establish procedures for inspection and abatement of mold hazards in residential buildings and school facilities, and certification programs for mold inspectors and mold hazard abatement workers

**S-2957/A-4712 (Stack/Mukherji, Chaparro)** – Establishes five-year moratorium on conversions of certain residential rental premises in qualified counties

**S-2958/A-4535 (Sarlo, Oroho/Zwicker, DePhillips, DeCroce)** – Establishes the "Energy Infrastructure Public-Private Partnership Act"

**S-3062/A-2049 (Ruiz, Greenstein/Howarth, Benson, Murphy)** – Provides corporation business tax and gross income tax credits for businesses that employ apprentices in DOL registered apprenticeships

**S-3063/A-4655 (Ruiz/Armato, Vainieri Huttie, DeAngelo)** – Provides tuition fee waiver apprenticeship courses



**S-3137/A-1308 (Sweeney, Oroho, Singleton/Greenwald, Milam, Land)** – The "Electronic Construction Procurement Act"

**S-3252/A-4713 (Greenstein, Stack/DeAngelo, Quijano)** – "New Townhouse Fire Safety Act"; requires automatic fire sprinkler systems in new townhomes

**S-3263/A-4837 (T. Kean, Diegnan/Vainieri Huttle, Chiaravalloti, McKnight)** – Revises and updates membership and purpose of Advisory Council on the Deaf and Hard of Hearing in DHS

**S-3270/A-5095 (Pou/McKeon, Freiman, DeCroce)** – Establishes certain requirements for stop loss insurance offered to small employers

**S-3393/ACS for A-5384 and 5157 (Sarlo, Addiego/Mazzeo, Murphy, Houghtaling, Calabrese, Armato, Dancer)** – Allows certain preserved farms to hold 14 special occasion events per year; imposes further event restrictions on residentially-exposed preserved farms

**S-3770/A-6118 (Sarlo, Oroho, Sweeney/Greenwald, Jones)** – Establishes "New Jersey Economic and Fiscal Policy Review Commission" to provide ongoing review of State and local tax structure, economic conditions, and related fiscal issues

**S-3888/A-5585 (Ruiz/Dancer, Pintor Marin)** – Extends document submission deadlines under Economic Redevelopment and Growth Grant program and Urban Transit Hub Tax Credit program

**S-4035/A-5702 (Pou, Singleton/Wimberly, Reynolds-Jackson, Sumter)** – Makes Fiscal Year 2020 supplemental appropriation of \$1,700,000 for Thomas Edison State University

**S-4281/A-6094 (Smith, Diegnan/Danielsen, Pinkin)** – Requires State to sell and convey to Educational Services Commission of New Jersey certain land and improvements known as Piscataway Regional Day School

**S-4331/A-4727 (Diegnan, Madden/Karabinchak, Holley, Jones)** – Requires person taking written examination for permit to watch video of rights and responsibilities of driver stopped by law enforcement; requires testing on rights and responsibilities of driver stopped by law enforcement

**A-491/S-4340 (Jimenez/Sacco, Stack)** – Enhances PFRS accidental death pension for surviving spouse by providing for minimum of \$50,000 annually

**A-1044/S-1441 (Houghtaling, Downey, DiMaio, Space/Doherty, Madden)** – Requires Director of Division of Taxation to examine feasibility of centralized property tax information system to verify property taxes paid by homestead property tax reimbursement claimants

**A-1045/S-2856 (Houghtaling, Downey, Dancer/Gopal, Oroho)** – Clarifies sales tax collection responsibilities of horse-boarding businesses in New Jersey

**A-1526/S-1048 (Zwicker, Johnson/Vitale)** – Concerns payment of independent contractors

**A-2731/S-3407 (Taliaferro, Space/Sweeney, Oroho)** – Removes statutory limitation on number of permits that may be issued by Division of Fish and Wildlife for the taking of beaver

**A-4382/S-2815 (Pinkin, Lopez, Kennedy/Beach, Smith)** – Requires paint producers to implement or participate in paint stewardship program

**A-4463/S-3927 (Freiman, Egan, Karabinchak/Oroho, Andrzejczak)** – Establishes "Electronic Permit Processing Review System"

**A-4788/S-3880 (Karabinchak, Freiman, Calabrese/Diegnan)** – Establishes expedited construction inspection program

**A-5072/S-3496 (Karabinchak, Johnson, Mukherji/Greenstein, Cryan)** – "Defense Against Porch Pirates Act"; creates new category of theft, with penalties including mandatory restitution and community service, for taking package delivered to residence by cargo carrier

**A-5446/S-3907 (Land, Reynolds-Jackson, Verrelli/T. Kean, Lagana)** – Requires reporting of opioid deaths

**A-5629/S-3980 (Pintor Marin, Munoz/Weinberg, Corrado)** – Clarifies provisions concerning disclosure of existence and content of discrimination or harassment complaints; requires certain disclosures to person against whom complaint is made

[Copy of Statement](#)

**ACS for A-5922 and 5923/SCS for S-4223 and 4224 (Conaway, Vainieri Huttle, Lopez, Pinkin/Vitale, Sweeney)** – Revises requirements for sale of tobacco and vapor products; increases penalties for prohibited sales; increases fees for cigarette and vapor business licensure

[Copy of Statement](#)